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ABSTRACT 
 
The aim of this study was to determine if there are similarities and/or differences with 
regards to function, tone and strength between children with spastic diplegia as a 
result of CP and HIV encephalopathy as the prevalence of HIV infected children with 
diplegia has increased since the advent of HAART.  
Participants with spastic diplegia (GMFCS I to IV) between the ages of four and 
sixteen were consecutively selected at two state hospitals and two private practices 
in Johannesburg. Thirty three HIV infected and thirty one HIV uninfected participants 
were assessed using a Gross Motor Function Measure 66 (GMFM-66), Functional 
Mobility Scale (FMS), Modified Ashworth Scale for tone, and a hand-held 
dynamometer for strength.  
There were no statistically significant differences between the two groups for 
function, strength and tone. When the groups were separated into functional 
(GMFCS I and II) and non-functional groups (GMFCS III and IV), there were no 
statistically significant differences between the HIV infected and HIV uninfected 
participants for function (functional group p=0.52, non-functional group p=0.74), tone 
and strength. There was a clinically important difference found for the GMFM-66 in 
the functional group in favour of the HIV infected participants. There was a trend for 
the HIV infected functional participants to be weaker and have milder tone compared 
to their HIV uninfected counterparts while the non-functional HIV infected participants 
tended to have milder tone and be stronger than their HIV uninfected counterparts.  
In conclusion, the HIV infected group presented similarly to the HIV uninfected group. 
The lack of gait analysis and a small sample size once the initial group was stratified, 
are limitations of this study. Further research is required with larger sample sizes to 
verify the results of this study. 
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CHAPTER 1 - INTRODUCTION TO THE STUDY 
1.1 Introduction 
Cerebral Palsy (CP) is a well-recognised neurodevelopmental condition beginning early in 
infancy and continuing into adulthood (Rosenbaum et al, 2007). Permanent injury to the 
developing brain precipitates abnormal postures and movement pattern that affect activity 
and participation. It primarily affects motor function but disturbances of sensation, 
perception, cognition, communication, and behaviour can accompany the motor deficit 
(Rosenbaum et al, 2007).  
Spastic diplegia is the term used to describe children with CP with mainly motor deficits, 
like muscle weakness and spasticity, in the lower limbs. It is associated with periventricular 
leukomalacia (PVL) as a result of prematurity (Bottcher, 2010). These children usually 
walk independently and have a distinct gait pattern that has been identified by Rodda et al 
(2004). There has been much research in the field of CP with specific attention to muscle 
strengthening, natural progression into adolescence, the impact of impairments on function 
and quality of life in children with spastic diplegia (Jaspers et al 2013; Calley et al 2012; 
Ferland et al, 2012; Kim and Park, 2011; Nyström Eek et al, 2011; Ross and Engsburg, 
2007; Bell et al, 2002). 
Globally, an estimated 36.7 (34-39.8) million people were living with HIV in December 
2015. Sub- Saharan Africa accounts for 69% of the people living with HIV worldwide as 
well as 90% of the children infected with the virus (UNAIDS, 2015). In South Africa, there 
has been an increase in HIV prevalence from 5.5 to seven million people from 2008 to 
2015. This is attributed to an increase in people accessing highly active antiretroviral 
therapy (HAART) and a corresponding increase in the life expectancy of people living with 
HIV. The prevalence of children under the age of fifteen living with HIV in South Africa has 
decreased from 300 000 in 2012 to 240 000 in 2015. According to 2015 statistics, 73% of 
infected children in South Africa are receiving HAART. Globally, 49% of children infected 
with HIV were accessing HAART in 2015 which has increased from 21% in 2010 
(UNAIDS, 2015). 
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Early invasion of the central nervous system (CNS) by the virus affects the developing 
foetal and infant brain. This results in the most common primary HIV-related CNS 
complication: HIV encephalopathy (Whitehead et al, 2014; Langerak et al, 2013; Hilburn et 
al, 2010). Children who develop HIV encephalopathy usually present within the first two 
years of life (Hilburn et al, 2010) and have significant delays in motor, cognitive and 
language areas (Bailieu and Potterton, 2008; Hilburn et al, 2010; Donald et al, 2014a; 
2014b). 
The introduction of HAART has improved the survival and prolonged the quality of life of 
HIV-Infected children (Hilburn et al, 2010; van Rie et al, 2009). HAART may inhibit or delay 
HIV dissemination in the CNS. Several studies have shown that there has been a decline 
in the incidence of HIV encephalopathy since the increase in the use of HAART 
(Whitehead et al, 2014; van Rie et al, 2009). However, it does not reverse the damage that 
has already occurred (Smith et al, 2008). Therefore it allows for increased survival, 
meaning that a greater number of children are reaching school-going age but often with 
severe developmental delay (Potterton et al, 2016; Hilburn et al, 2010). 
One of the residual impairments of HIV encephalopathy is diplegia (Donald et al, 2015; 
Langerak et al, 2014; Govender et al, 2011). Langerak et al, (2014) assessed children with 
spastic diplegia as a result of HIV encephalopathy in order to present a first description of 
gait and physical status. Their results showed two distinct patterns of gait which could not 
be classified in the typical spastic diplegic CP gait that was described by Rodda et al, 
(2004).   
Children with diplegia as a result of CP or HIV encephalopathy have different 
pathogenesis but present with similar motor deficits, indicative of an upper motor neuron 
lesion. However, due to the paucity of literature in the field of spastic diplegia as a result of 
HIVE, it is unclear whether these groups have similar impairments, activity limitations and 
if their disability will follow the same progression as that of children with CP. 
1.2 Problem Statement 
In the South African  as well as worldwide context, there are limited studies which have 
investigated and compared the clinical presentation of children presenting with spastic 
diplegia as a result of HIVE in comparison to HIV uninfected children with diplegia. 
Therefore it is uncertain if HIV infected children with diplegia have the same clinical 
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presentation in terms of impairments and function as children with diplegia who are HIV 
uninfected.  
1.3 Research Question 
Do HIV infected children with diplegia have a similar clinical presentation to HIV uninfected 
children with diplegia across GMFCS levels I-IV? 
 1.4 Aim of the study 
To aim of this study was to determine whether the clinical presentation of HIV infected 
children with diplegia is similar to that of HIV uninfected children with diplegia with regards 
to gross motor function, muscle strength and tone in a South African setting. 
1.5 Objectives of the study 
1. To compare measured anthropometric  and demographic data of the two 
groups 
2. To  determine  and compare the functional status of children with diplegia  in 
the HIV-infected and uninfected groups, across GMFCS levels I-IV according 
to the GMFM-66 and FMS assessments  
3. To determine the spasticity of the subjects using the Modified  Ashworth 
Scale and compare the results of the HIV infected and uninfected groups 
4. To determine and compare the muscles strength of the HIV infected and HIV 
uninfected participants using a hand held dynamometer  
1.6 Significance of the study 
This study will provide insight into the clinical presentation of HIV infected and non-
infected children with diplegia. The information obtained from this study will help 
clinicians better understand the clinical picture of spastic diplegia as a result of HIV. 
This will guide health professionals in making more informed, evidence-based 
decisions with regard to neurological and orthopaedic management as well as 
rehabilitation of these children. This study will begin to fill some of the gaps that are 
evident in this field and will form the base upon which future research can be 
conducted. 
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1.7 Conclusion 
Neurodevelopmental delay in terms of motor, cognitive and language impairment as a 
result of HIVE has been well documented. With the advent of HAART, HIV infected 
children are surviving but with this comes an increase in co-morbid complications that are 
not life-threatening but still have an adverse effect on activity and participation.  Spastic 
diplegia is a known presentation of HIVE but has a different pathogenesis to spastic 
diplegia as a result of CP. It is important to determine if HIV infected children with diplegia 
present similarly to HIV uninfected children with diplegia in a South African setting. 
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CHAPTER 2- LITERATURE REVIEW 
 
2.1 Introduction 
This literature review will serve to provide an overview of three areas. Firstly, the definition 
and global incidence of cerebral palsy will be described and the clinical picture of spastic 
diplegia will be further elaborated on. Secondly, it will serve to describe the incidence and 
prevalence of HIV and HIVE in children in South Africa. HIVE will be discussed in terms of 
the definition, clinical picture as well as the effect of HAART on HIVE. Lastly, an overview 
of outcome measures used in this study, to assess impairments, activity and participation 
in children with diplegia will be presented.   
Literature dating from 1996 to present was searched using PubMed, Cinahl and Google 
Scholar search engines. Articles were also physically sourced from the Health Sciences 
library at the University of the Witwatersrand. The following key words were used when 
searching: cerebral palsy, spastic diplegia, HIV in children, muscle strength and adverse 
effects of HIV encephalopathy. 
2.2 Cerebral Palsy 
2.2.1 Definition 
Cerebral Palsy (CP) is a well-recognised neurodevelopmental condition which begins in 
early childhood and persists through the child’s life. There have been many definitions of 
CP through the years. However, these definitions have not given sufficient importance to 
the non-motor neurodevelopmental disabilities of performance and behaviour that often 
accompany CP. They also didn’t take into account the musculoskeletal difficulties that 
often occur with advancing age (Rosenbaum et al, 2007). Therefore Rosenbaum et al 
(2007), proposed a new definition which would acknowledge these issues.  
“Cerebral Palsy describes a group of permanent disorders of the development of 
movement and postures causing activity limitations that are attributed to non-progressive 
disturbances that occurred in the developing fetal or infant brain. The motor disorders of 
CP are often accompanied by disturbances of sensation, perception, cognition, 
communication, and behaviour, by epilepsy and by secondary musculoskeletal problems” 
(Rosenbaum et al, 2007, pg 9). According to the annotations that have accompanied this 
definition, it was noted that the motor impairments manifest very early in childhood 
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development, usually before 18 months of age. Other neurodevelopmental and functional 
difficulties may become more evident later on. With regards to the term ‘fetal’ or ‘infant’ 
brain, there is no specified upper age limit, although the first two to three years of life are 
most important in the timing of the disturbances affecting the developing brain 
(Rosenbaum et al, 2007). This definition is more consistent with the biopsychosocial model 
of health as embodied in the WHO International Classification of Functioning, Disability 
and Health (ICF).  
2.2.2. Prevalence 
The global incidence of cerebral palsy is between two to three per 1000 live births (Tedla, 
2014; Tugui and Antonescu, 2013). This has been consistent over the last fifty years due 
to the increasing survival of premature infants (Tugui and Antonescu, 2013). According to 
a systematic review of CP in the African context, the prevalence is between two to ten per 
1000 children in community-based samples (Donald et al, 2014a). 
2.2.3 Aetiology and Risk Factors 
According to the latest definition, CP results from injury to the developing brain. This can 
occur prenatally, perinatally and postnatally (Rosenbaum et al, 2007; Krigger, 2006). 
Prenatally acquired CP occurs from largely unknown causes (Krigger, 2006). Intra-uterine 
infection is the best known risk factor in this group. The risk of CP increases in very low-
birth weight infants with a history of prenatal sepsis. CP is more prevalent among low birth 
weight infants in comparison to normal birth weight infants. Periventricular leukomalacia is 
one of the main causes of CP in pre-term infants (Odding et al, 2006). 
Risk factors for perinatally acquired CP include birth asphyxia, neonatal convulsions, 
jaundice and infection, and instrument-assisted delivery. The risk of developing CP 
increases with multiple pregnancies. The prevalence of CP in single pregnancies is 2.3 per 
1000 births, 112.6 per 1000 births in twins and 44.8 per 1000 births in triplets (Odding et 
al, 2006). 
Postnatal causes account for 10 to 20% of all cases of CP. Brain damage can be caused 
by bacterial meningitis, encephalitis, hyperbilirubinaemia, trauma and abuse (Krigger et al, 
2006).  
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In the African context, the most common reported risk factors were birth asphyxia, 
kernicterus and neonatal sepsis. Prematurity was only identified as a major cause in two of 
the sixteen studies reviewed (Donald et al, 2014a). 
2.2.4 Clinical features of CP 
Impairments as a result of CP result in activity limitation as well as participation restriction. 
These musculoskeletal impairments include spasticity, contractures, abnormal bone 
growth, poor balance, weakness and poor selectivity of movement (Kim and Park, 2011; 
Krigger et al, 2006; Odding et al, 2006).  
When growth parameters of CP children were assessed and compared to normally 
developing gender and age-matched peers, children with spastic quadriplegia showed a 
statistically significant decrease in height, weight and head circumference. Children with 
spastic diplegia also had decreased growth parameters compared to the control group but 
were not statistically significant. In this study, weight was found to be the only growth 
parameter to predict gross motor abilities (Ibrahim and Hawamdeh, 2007). Poor growth 
and malnutrition are common amongst children with CP. However, those who have 
marked increase in spasticity and are inactive are also at risk of developing obesity. -Poor 
growth can be attributed to poor nutritional intake or impaired oro-motor control and 
swallowing. Non-nutritional factors like immobility and inactivity may also be contributing 
factors. This increases the risk for sub-optimal growth as there is decreased mechanical 
stress placed on the bone therefore decreased bone growth (Bell et al, 2010).  
Children with CP are also known to have decreased physical fitness and other 
impairments like cognitive and intellectual impairments, epilepsy, visual and hearing 
impairments, speech impairments and difficulties with feeding (Odding et al, 2006; Krigger 
et al, 2006). Epilepsy was the most common reported co-morbidity of CP in Africa which is 
consistent with developed countries (Donald et al, 2014a). Approximately one third of 
school-going children with CP in a developed country experience behavioural difficulties. 
These range from peer problems (55.3%) and hyperactivity (30.3%) to emotional problems 
(40.8%). These were found to be unrelated to socio-economic, physical or cognitive 
characteristics, hence an additional cause of stress for the child and family (Brossard-
Racine et al, 2012). 
A thorough physical and radiological examination is necessary when making the diagnosis 
of CP. Almost seventy percent of children with spastic CP have abnormal MRI findings. 
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Radiological abnormalities can include brain malformations, cortical lesions and 
abnormalities of the peri-ventricular white matter (Odding et al, 2006). 
2.2.5 Classification of CP  
Classification of CP is done according to the type of movement disorder and the 
anatomical distribution of the abnormal movements.Abnormal movements can be divided 
into two groups namely: spasticity and dyskinetic. Spasticity is the more frequent disorder 
affecting 60%-80% of children with CP (Tugui and Antonescu, 2013; Bottcher, 2010; 
Krigger, 2006). 
Spasticity has been defined in various ways. These include: muscle hypertonia, velocity-
dependent stretch to passive movement, stiffness in a muscle during active movement and 
increased deep tendon reflexes (Krigger, 2006; Ross and Engsburg, 2002). Spasticity is 
the result of a lesion or injury to the pyramidal tract (Tugui and Antonescu, 2013).   
Dyskinetic, athetoid and ataxic types of CP form the minority of cases. Athetoid and 
dyskinetic features include writhing type involuntary movements and fluctuating tone, while 
ataxic children with CP have problems with balance and coordination as a result of a 
lesion to the extra-pyramidal tracts (Tugui and Antonescu, 2013; Krigger, 2006). 
Classification of CP can also be done according to the anatomical distribution of the motor 
deficit. Therefore classifications can include monoplegia (one limb affected), hemiplegia 
(one half of the body affected), diplegia (lower limbs more affected than upper limbs) and 
quadriplegia (all four limbs affected) (Tedla, 2014; Tugui and Antonescu, 2013).   
2.2.6 Gross Motor Function Classification Scale (GMFCS) 
Classification of CP traditionally looked at the condition from an impairment level. In this 
setting, mild, moderate and severe were the terms used to describe the severity of the 
motor impairment, while classification was based on the predominant area of the body that 
was affected. For example, spastic diplegia was the term used to describe a child with CP 
with predominant motor deficits in the lower limbs. Rosenbaum et al (2007) suggested that 
this manner of classification is not reliable as there is little uniformity between clinicians.   
The Gross Motor Function Classification System (GMFCS) was developed by Palisano et 
al (1997) to provide a standard classification system that could be understood by both 
clinicians and parents of children with CP under the age of 12 years. Initially it consisted of 
five levels of functional abilities across four age bands. The age bands were designed to 
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account for age-related differences in gross motor function. The five levels were 
determined through a process evaluating elements of motor function. The CanChild Centre 
for Childhood Disability Research has been responsible for the development of the Gross 
Motor Function Measure (GMFM) as well as the GMFCS in order to help clinicians have a 
better understanding of gross motor function in children with CP. The GMFM is the gold 
standard outcome measure used by healthcare professionals to measure gross motor 
function in children with CP (Russell et al, 2000). 
In order to establish validity and reliability of the GMFCS, a nominal group and Delphi 
survey consensus was used by Palisano et al, (1997). Seventy-seven children were 
classified by 51 therapists. The GMFCS has been found to have good inter-rater reliability 
(kappa of 0.75) (Palisano et al, 1997) and a high correlation (ICC -0.91) to the GMFM 
(Rosenbaum et al, 2014; Palisano et al, 2008). This indicates that there is an inverse 
relationship between these measures because higher numbered GMFCS levels represent 
children with lower function whereas a higher GMFM score indicates higher function 
(Palisano et al, 2000). The GMFCS has been shown to have content validity with an 
agreement of 80% predictive validity (positive of 0.74 and negative of 0.90), high inter-rater 
reliability (kappa of 0.75) and has evidence of stability over time (Rosenbaum et al, 2014; 
Palisano et al, 2008; Beckung et al, 2007; Palisano et al, 2000; Palisano et al, 1997).  
The GMFCS was expanded and revised (GMFCS E&R) in 2008 to coincide with the ICF 
framework of activity and participation and to include an additional age band of 12 to 18 
years. This was necessary to account for growth related changes that may affect function 
during puberty. Again, Palisano et al (2008) used a nominal group technique as well as 
Delphi survey to determine the content validity. Through this process the GMFCS-E&R 
was found to have content validity with an agreement of 80%. In revising this system, 
statements were reworded to distinguish between methods of mobility so as to have clear 
definitions of each level (Rosenbaum et al, 2014; Palisano et al 2008). 
The GMFCS E&R consists of five ordinal levels. Each level describes the child’s ability in 
sitting and walking and the need for assistive devices such as walkers and wheelchairs 
(See Table 2.1). The distance between the levels is not considered to be equal nor is it 
assumed that children with CP are equally distributed across the five levels (Beckung et al, 
2007; Palisano et al, 2000). In order to differentiate between levels, one needs to evaluate 
the need for assistive mobility devices, as well as assistive technology, rather than quality 
of movement (Beckung et al, 2007; Palisano et al, 2000). Currently, it includes a 
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description of the child’s ability at each level across different age levels. This was done to 
include age appropriate activities and participation. The age bands are: 1) less than two 
years, 2) two to four years, 3) four to six years, 4) six to twelve years and 5) twelve to 
eighteen years (Rosenbaum et al, 2014; Palisano et al 2008). 
Not only is it a stand-alone measure that can be used by parents and professionals without 
the need for training (Rosenbaum et al, 2007), it is also a reliable tool and has become the 
principal way to describe motor disability for children with CP (Rosenbaum et al, 2014; 
Palisano et al 2008; Palisano et al, 1997). 
Table 2.1 Gross Motor Function Classification System (E&R) (Palisano et al, 2008) 
Level I Walks without restrictions, limitations in more advanced gross motor skills 
Level II Walks without restrictions, limitations walking outdoors and in community 
Level III Walks with assistance of mobility device, limitations walking outdoors and in 
community 
Level IV Self mobility with limitations. Children are transported or use power mobility 
outdoors and in the community 
Level V Self mobility is severely limited even with the use of assistive technology 
 
Impairments, behaviour and environmental factors can determine gross motor function 
outcome. Primary impairments of poor postural stability followed by the distribution of 
involvement, decreased quality of movement and spasticity (β=0.52-0.68) together with 
secondary impairments of muscle strength, decreased range of movement and decreased 
endurance (β=0.25-0.26) have a significant impact on function in all classifications of CP. 
Adaptive behaviour was also found to be a significant determinant of function in children 
with GMFCS level III to V (Bartlett et al, 2014). Using a path model analysis, Kim and Park 
(2011) showed that spasticity has a significant negative effect, while strength had a 
significant positive effect on gross motor function. However, Ostenjø et al (2004) found a 
complex relationship between spasticity, range of movement (ROM), selective motor 
control and gross motor function. Children with GMFCS I and II had decreased spasticity, 
fewer deviations in ROM and better selective dorsiflexion compared to children with 
GMFCS III and IV. In this way they indirectly affect overall activity and participation of 
children with CP (Kim and Park, 2011; Ostenjø et al, 2004).  
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In order to enhance the interpretation of the GMFM and the GMFCS, the researchers at 
the CanChild Centre developed the Gross Motor Function Curves (Appendix 14). The 
curves assist in determining if a child’s gross motor function is in line with the expectation 
for children of the same age and GMFCS level. Data was transformed into age-90 values, 
which is the age by which children are expected to attain ninety percent of their motor 
potential. The expected scores for each level and the age at which the child is expected to 
achieve it are shown in Table 2.2 (Rosenbaum et al, 2002). These curves have been 
further elaborated on to improve their clinical use. Hanna et al (2008) created reference 
curves for each GMFCS level from the third to the ninety-seventh percentile. Beckung et al 
(2007) used these curves to predict gross motor outcomes in children with CP up to the 
age of fifteen while Hanna et al (2009) evaluated the stability and decline of the curves as 
children with various GMFCS levels moved into adolescence and adulthood. 
Table 2.2 Expected GMFM scores for each GMFCS level (Rosenbaum et al, 2002) 
GMFCS Level GMFM-66 Limit (50% range) Age-90 (years) (50% range) 
I 87.7 (80.1-92.8) 4.8 (4.4-5.8) 
II 68.4 (59.6-76.1) 4.4 (3.3-5.8) 
III 54.3 (48.5-60.0) 3.7 (2.5-5.5) 
IV 40.4 (35.6-45.4) 3.5 (3.5) 
V 22.3 (16.6-29.2) 2.7 
 
Beckung et al (2007) analysed the progression of gross motor development in children 
with CP over a four year period for all five GMFCS levels. Children with GMFCS level I and 
II were able to reach 90% of the maximum GMFM score at a median of five years. GMFCS 
III children reached 80% of the GMFM by the age of seven years. Children at GMFCS IV 
and V were only able to reach 30 and 20% of the GMFM score by age five and seven 
years respectively. Children with diplegia were the majority in GMFCS II and III groups.  
Overall, for all CP subtypes, there was a gross motor plateau at the age of six to seven 
years which was consistent with Rosenbaum et al (2002).  
The gross motor function of  657 children with CP who were followed into adolescence and 
adulthood in order to determine the stability or decline of function. Children at GMFCS I 
and II showed no decline into adolescence. Children at level III peaked at 7 years 
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11months, while children at GMFCS IV and V peaked at 6 years11 months. These three 
levels showed a decline in GMFM score by 4.7, 7.8 and 6.4 points as they moved from 
adolescence to adulthood. This decline is seen to be significant and provides evidence 
that children at levels III, IV and V are at a greater risk of losing function. This may be 
attributed to increase in energy cost, increased contracture and deformity and increase 
stiffness (Hanna et al, 2009). 
The natural progression in children with CP as they move from childhood into adolescence 
and adulthood is one of plateau then decline as they get older. The Gross Motor Function 
Curves have been found to be valid and reliable and are useful in being able to predict 
gross motor function according to GMFCS level in children with CP (Hanna et al, 2009; 
Beckung et al, 2007). 
2.3 Spastic Diplegia 
Children with spastic diplegia were traditionally identified as children whose lower limbs 
were more affected than their upper limbs. It is associated with periventricular 
leukomalacia (PVL) as a result of prematurity (Bottcher, 2010). 
Periventricular leukomalacia results in dilatation of the ventricles and reduction of the white 
matter. The disruption of the motor tracts results in motor deficits. It is also thought that the 
white matter tracts connecting the prefrontal and posterior brain region may be affected. 
This will affect other brain functions like information processing and cognitive function. 
Executive function is the last cognitive area to mature and this occurs well into 
adolescence. It is defined as “the ability to control impulses, anticipate consequences, 
establish goals, plan, monitor results and use feedback and they are thought to regulate 
both immediate behaviour and planning towards long-term goals.” (Bottcher et al, 2010, pg 
42). Children with diplegia may present with specific cognitive impairments in visual 
perception, attention, speech and language and executive function which results in 
learning difficulties. This can affect the child’s participation in school and make him or her 
more prone to behavioural problems (Bottcher, 2010; Bottcher et al, 2010). This together 
with the primary motor and postural disabilities can limit a child’s activity, restrict 
participation and negatively impact on quality of life.   
When quality of life was assessed in ambulant children with CP, lower limb spasticity, 
severe gait pathology and slow gait speed played an important role in the domains of 
social well being, impact of disability and pain (Jaspers et al, 2013). Similarly when activity 
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and participation in relation to quality of life, was compared to that of age-matched typically 
developing children, children with CP experienced lower levels of participation across 
community life, personal levels of care and recreation, as well as lower quality of life with 
respect to function. This was mainly due to their physical restrictions which affected 
function and mobility (Calley et al, 2012).  
Motor disability is regarded as the primary manifestation of CP. These restrictions of 
function and mobility can be due to trunk weakness, poor balance and intellectual 
impairment (Tedla, 2014). Muscle weakness is an important and well-documented 
characteristic of children with diplegia (Tedla, 2014; Nyström et al, 2008; Ross and 
Engsburg, 2007; Wiley and Damiano, 1998). Children with spastic diplegia can usually 
walk independently and have a distinct gait pattern (Rodda et al, 2004). These 
impairments will be discussed further. 
2.3.1 Gait pattern in spastic diplegia  
Rodda et al (2004) analysed the gait of 187 children with diplegia in order to provide a 
description of the typical diplegic gait patterns. Their classification of gait was based on the 
position of the ankle followed by that of the knee, hip and pelvis and was demonstrated to 
be reliable (kappa of 0.74). They identified five different patterns namely: true equinus, 
jump gait, apparent equinus, crouch and asymmetrical gait. Table 2.3 summarises the 
components of each pattern. Not described in the table, is the mild gait in which the 
subjects mainly presented with in-toeing but other kinematics at the hip, knee and ankle 
fell within the normal range. Younger children presented most commonly with true equinus 
and jump gait pattern whereas apparent equinus and crouch were more commonly seen in 
older children. This suggests that there may be a natural gait progression as children get 
older (Rodda et al, 2004).  
The natural progression of gait in children with CP is due to increasing growth and age. 
Bell et al (2002) evaluated this progression over time using three-dimensional kinematics, 
temporal and stride parameters, as well as clinical examination measures in children with 
CP who had not had any orthopaedic intervention. Two assessments were completed four 
years apart. They had a small sample of 28 children of which 19 were classified as 
diplegic. Their results indicated that gait function decreased with respect to stride 
measures, range of motion and kinematic parameters over a four year period. Factors 
contributing to this decline included increasing body weight, the ratio of body weight to 
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strength, development of contractures and compliance with physiotherapy (Bell et al, 
2002). 
There is a positive correlation between gait and muscle strength. Improving muscle 
strength in the lower limbs can positively improve gait function (Nyström Eek et al, 2011; 
Nyström Eek et al, 2008; Ross and Engsburg, 2007). 
Table 2.3 Sagittal Gait patterns in Spastic Diplegia (Rodda et al, 2004) 
 Ankle Knee Hip Pelvis  
True Equinus 
Equinus Extends fully Extends fully Neutral or 
anterior tilt 
Younger 
children 
Jump Gait 
Equinus Flexed in early 
stance and 
extend in late 
stance 
Flexed in early 
stance and 
extend in late 
stance 
Neutral or 
anterior tilt 
Younger 
children 
Apparent 
Equinus 
Normal range Flexed 
through stance 
Flexed 
through stance 
Neutral or 
anterior tilt 
 
Crouch Gait 
Increased 
dorsiflexion 
Flexed 
through stance 
Flexed 
through stance 
Normal or 
posteriorly 
tilted 
 
Asymmetric 
Gait 
Subjects’ two lower limbs are classified as belonging to two different groups. 
  
2.3.2 Muscle strength and spasticity in spastic diplegia  
Muscle weakness and spasticity are known impairments of CP (Ferland et al, 2012; Ross 
and Engsburg, 2007; Ross and Engsburg, 2002). It is well documented that compared to 
their typically developing peers, children with CP have less strength in their affected areas 
(Dekkers et al, 2014; Thompson et al, 2011; Wiley and Damiano; 1998). 
Lower limb strength profiles for spastic CP were documented by Wiley and Damiano in 
1998. A hand-held dynamometer was used to assess the strength of lower limb muscles in 
30 ambulatory children with spastic diplegia and hemiplegia as well as 16 age-matched 
typically developing children. The age range was between five and twelve years old. Eight 
muscle groups were assessed using the break test. The force value for each muscle group 
was normalised for body weight for better comparison across age groups and recorded as 
Newtons per kilogram (N/kg). This study provided evidence that children with CP were 
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significantly weaker than age-matched typically developing children and that weakness 
was more prevalent distally compared to proximally (Wiley and Damiano, 1998). 
Ross and Engsburg have conducted several studies to investigate muscle strength in 
children with CP. In 2000, Engsburg et al investigated the relationship between hip 
spasticity and strength in spastic diplegia. Forty-four children with CP as well as typically 
developing children were assessed. Their results showed that hip adductor tone was 
significantly higher and hip strength measures were significantly lower in children with CP.  
In 2002, Ross and Engsburg investigated the relationship between spasticity and strength 
in individuals with spastic diplegia. These results were compared to results of 50 
individuals without disability. Spasticity was assessed at the ankle plantar flexors and the 
knee flexors while strength was assessed at the knee flexors and extensors and ankle 
plantar and dorsiflexors. Results from this study were clinically significant. It showed that 
spasticity was not related to strength and could not be the cause for muscle weakness that 
was found in children with spastic diplegia. They concluded that muscle weakness was a 
significant impairment in these individuals as it was present in all subjects while spasticity 
was not. There was no significant correlation between the amount of spasticity in a muscle 
group to the amount of strength in agonist and antagonist groups. Their results supported 
previous literature in that spasticity was more prevalent distally than proximally in children 
with spastic diplegia. In 2007, they investigated the relationship between spasticity, 
strength, gait and the GMFM-66 in children with spastic diplegia. Their results showed that 
strength correlated significantly to function (r=0.83) and gait speed as compared to 
spasticity (r=0.27). A KinCom dynamometer was used in all the above studies to measure 
strength and spasticity (Ross and Engsburg, 2007; Ross and Engsburg, 2002; Engsburg 
et al, 2000). 
 
Similarly Nyström et al have conducted several studies to investigate the impact of muscle 
strength and training on gait in children with CP. In the first study, they investigated the 
effect of strength training on gait function. The muscle strength of sixteen children with 
GMFCS level I and II were assessed pre and post intervention. Muscle weakness was 
most pronounced at the ankle followed by the hip (Nyström et al, 2008). Their results 
showed that muscle strengthening program has a positive effect on muscle strength as 
well as gait. In 2011, they elaborated on this relationship between gait and muscle strength 
but focused on gait kinematics. Twenty children with CP were compared to twenty typically 
developing children with regards to muscle strength and gait kinetics. All the lower limb 
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muscles were found to be weaker and the gait moment and power at the ankle was 
significantly lower in children with CP. There was a significant correlation between the 
muscle strength of six out of eight muscle groups and ankle generating power. This 
highlighted the importance of the plantar flexors during gait and more importantly that 
overall muscle strength in the lower limb is vital for the plantar flexors to generate the 
power required during gait. In both the above studies a myometer was used to assess 
muscle strength using the ‘make test’ method. All force values were recorded as torque 
(Nm) and then normalised for body weight (Nyström Eek et al, 2011; Nyström Eek et al, 
2008).  
Evidence of plantar and dorsiflexor weakness in children with CP as a result of an inability 
to produce the desired torque as well as inability to maximally activate the muscle was 
found by Elder et al (2003). Furthermore, these investigators determined that the cross-
sectional area of the gastro-soleus muscle was much smaller in children with CP 
compared to normally developing counterparts (Elder, 2003). 
Muscle strength is important for achieving function other than walking. This relationship 
between strength and function was assessed in two studies. In the first study lower limb 
strength in fifty ambulant children with CP was assessed using the ‘make’ test. Muscle 
strength was recorded as torque. In addition to muscle strength being weaker than the 
control group, the researchers also found an inverse relationship between strength and 
increasing GMFCS levels. The greatest reduction in strength from GMFCS I (independent 
walkers) to GMFCS III (walking with assistive device) was in the hip abductors (61%) and 
knee extensors (30%) (Thompson et al, 2011). The second study assessed strength in 
relation to overall locomotor function by using the Six Minute Walk Test, 10-meter Shuttle 
Run Test and Timed Up and Down Stairs Test. Hip flexor and ankle plantar flexor strength 
were associated with walking (47.8%) and stair climbing (32.9%) while hip abductors was 
associated with running (43.5%) (Ferland et al, 2012). 
Muscle strengthening in children with CP has been studied to understand its effect on 
function. A randomised controlled trial in which a twelve week progressive resistance 
training program was administered to children in the intervention group while the control 
group received ongoing therapy showed that a strengthening program had a positive effect 
on muscle strength but this was not carried over into an improvement in mobility (Scholtes 
et al, 2008). This was supported by another study that sought to determine if a 
strengthening program would impact on daily physical activity like number of steps taken 
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and time spent sitting or lying in children with CP. The results of this study showed that an 
improvement in strength did not translate into an improvement in physical activity (Bania et 
al, 2016). The authors have suggested that strengthening needs to be context-specific 
rather than generalised strengthening to have a positive impact on activity and function.  
A randomised controlled trial was conducted to determine the effect of a six week 
strengthening program on balance in children with diplegia. The experimental group 
received a specific strengthening program for lower limb and trunk muscles as well as 
conventional therapy while the control group received only conventional therapy. There 
were significant improvements in the experimental group for strength, balance and GMFM 
as compared to the control group (Tedla, 2014). 
The above studies indicate that there is a correlation between muscle strength, gait and 
function in children with spastic diplegia but there is no consensus as to which muscle 
groups are consistently weak. In addition it has been shown that strengthening programs 
alone, do not improve function and activity.  
Only one study was found which suggested that muscle strength could be an important 
factor in standing in children with CP.  Lidbeck et al (2015), using 3D analysis, assessed 
the muscle strength of hip flexors, knee extensors, ankle plantar and dorsiflexors as well 
as standing posture. Muscle strength was assessed in a seated position but was analysed 
with respect to both the child’s ability to stand and in the seated posture. Children standing 
with support presented with a more flexed posture but the same strength in the hips and 
ankle muscles as children standing without support. Hence, they have suggested that the 
sensory system deficits may also be a determining factor for standing. Further research is 
required in this regard (Lidbeck et al, 2015). 
To summarise, the above studies have shown that muscle strength and spasticity have an 
impact on standing and walking (Lidbeck et al, 2015; Ferland et al, 2012). Spasticity 
increases from proximal to distal in children with spastic diplegia (Ross and Engsburg, 
2002) but did not account for the greatest variance in gross motor function or gait (Ross 
and Engsburg, 2007). Muscle strength in children with CP has been found to be 
consistently weaker than typically developing children (Thompson et al, 2011; Wiley and 
Damiano, 1998). It is highly correlated to function and moderately to gait (Ross and 
Engsburg, 2007). Kim and Park (2011) found that strength and spasticity together 
accounted for 48.8% of the variance and are the causal factors in gross motor function. 
The results of this study must be interpreted with caution as there was a skewness 
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towards GMFCS level V. However, Ross and Engsburg (2002) found that there was no 
significant relationship between spasticity and strength at the knee and ankle in children 
with spastic diplegia GMFCS I and II. Muscle strengthening programs have proved to have 
a positive effect on strength (Bania et al, 2016; Tedla et al, 2014; Nyström et al, 2008; 
Scholtes et al, 2008) but not necessarily on function (Bania et al, 2016; Scholtes et al, 
2008). Therefore we can see that there is a complex relationship between spasticity, 
strength, selective motor control and function in children with CP. 
In conclusion, children with spastic diplegia as a result of CP have varying degrees of 
musculoskeletal impairments and cognitive impairments which lead to activity limitations 
and participation restrictions as compared to typically developing children of the same age. 
Spastic diplegia as a result of HIV will be explored in the next section. 
2.4 HIV  
 2.4.1 Prevalence of children infected with HIV in South Africa 
Globally 3.2 to 3.4 million children are estimated to be living with HIV. Sub –Saharan Africa 
is home to 90% of HIV infected children (Kukoyi et al, 2016; Donald et al, 2015; Vreeman 
et al, 2015).  
In South Africa the number of HIV infected children below the age of 14 has gone from 
1900 in 1990, to peaking at 380 000 in 2008 and then decreasing to 240 000 in 2015 
(UNAIDS, 2015). This decline may be attributed to the improved prevention of mother to 
child transmission (PMTCT) in South Africa which began in 2001. In the USA, the PMTCT 
programme has reduced the rate of vertical transmission to 2% (Donald et al, 2015; 
Vreeman et al, 2015; van Rie et al, 2007). According to UNAIDS Fact sheet (2015), since 
2010, there has been a 66% reduction in the number of new infections in children in the 
Eastern and Southern African region while 59% of adult women in this region were 
accessing HAART in 2015 (UNAIDS, 2015).  
Presently, in South Africa the PMTCT programme involves: initiation of anti-retroviral 
therapy during pregnancy in HIV infected women, all infants are tested at 6 weeks and 
prophylaxis is given to all HIV exposed infants. Access and adherence to PMTCT can be 
challenging in resource-limited settings (Donald et al, 2015). 
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2.4.2 Vertical Transmission of HIV  
Children are mainly infected by HIV through mother to child transmission or vertical 
transmission which may occur in utero (less than 10%), at the time of delivery (10-20%) or 
from breast milk (10-20%) (Hilburn et al, 2010). Twenty five to forty percent of HIV 
infection in children is as a result of mother-to-child transmission (Hilburn et al, 2010).  
High maternal viral load has been associated with an increased risk of mother-to-child 
transmission (Hilburn et al, 2010; Mirpuri and Jain, 2010). One of the issues affecting 
mother-to-child transmission is the maternal side effects of HAART. Mirpuri and Jain 
(2010) have reviewed several studies which had conflicting results on whether HAART 
increased the risk of prematurity. However, they noted that initiation of HAART prior to 
pregnancy or in the first trimester was more strongly associated to pre-term delivery as 
compared to if it was initiated in the second or third trimester (Mirpuri and Jain, 2010). 
Furthermore, elective caesarean sections are recommended when the maternal viral load 
is greater than 1000 copies per ml. This is done to reduce the rate of mother to child 
transmission but it also increases the rate of prematurity in neonates (Mirpuri and Jain, 
2010). 
2.4.3 Effect of highly active anti retroviral therapy (HAART) on HIV 
HIV drugs are classified into three main categories namely: 1) neucleoside or neucleotide 
reverse transcriptase inhibitors (NRTI’s), 2) non-neucleotide reverse transcriptase 
inhibitors (NNRTI’s) and 3) protease inhibitors (PI’s).  NRTI’s and NNRTI’s block viral 
replication while PI’s prevent cleavage of viral proteins (Donovan et al, 2013). HAART is 
defined as the use of a combination of three drugs from at least two different classes of 
HIV drugs (Patel et al, 2008). The combination of drugs depends on the patient’s previous 
exposure and resistance to HAART, age, tolerability and other co-existing illnesses 
(Donovan et al, 2013). 
The introduction of HAART has improved the survival and prolonged the quality of life of 
HIV infected children (Hilburn et al, 2010; van Rie et al, 2009). HAART became available 
in developed countries such as the USA in 1996.  Patel et al, (2008) conducted a study in 
the USA where they investigated the long-term effectiveness of HAART in children over a 
period of 10 years. The study included 1236 children who were part of the Paediatric AIDS 
Clinical Trials Group. Subjects were observed from 1996 (pre-HAART) to 2006. At each 
visit the data in the following categories were collected: sociodemographic characteristics, 
antiretroviral therapies and laboratory measurements.  During this period 70% of 
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participants had initiated HAART. They concluded that HAART use amongst children and 
adolescents was associated with significant lower mortality compared with non-HAART 
regimens. They suggested that HAART be used as first line therapy for children (Patel et 
al, 2008). In the USA mortality of HIV infected children has decreased by 90% since the 
introduction of HAART (Vreeman et al, 2015). However, this is not the same in resource-
limited settings where less than 25% of HIV infected children are receiving HAART (Kukoyi 
et al, 2016; Vreeman et al, 2015). 
The ideal time to initiate HAART in infants was investigated as part of the Children with 
Early Antiretroviral Therapy (CHER) trial in South Africa. Three hundred and seventy 
seven infants were enrolled and randomised into three groups namely, the deferred group 
or one of two early therapy groups. The deferred group only received treatment if the CD4 
count dropped to below 20% or clinical criteria were met. The early therapy group was 
divided into two arms: one in which therapy was administered early ( at a median age of 
7.4 weeks) but limited to 40 weeks and one in which it was administered early but limited 
to 96 weeks. Mortality was consistently higher in the deferred group. Their results also 
showed that HAART initiated at a median of seven weeks reduced early mortality from 
sixteen to four percent. This study provided strong evidence for early initiation of HAART in 
infants irrespective of CD4 count or clinical staging (Violari et al, 2008). 
In South Africa, the HAART regimen was instituted in 2004. Initially, Centre for Disease 
Control (CDC) criteria, were being used for administration of medication. This meant that 
infants and children had to either have a CD4 count lower than 15% or have an incident of 
opportunistic illness to begin the treatment. Thereafter at the end of 2010, treatment was 
being given to infants under the age of one year irrespective of disease stage (Potterton et 
al, 2013). A large study of over 3000 participants in sub-Saharan Africa, showed that from 
2005 to 2010 that the number of children initiating HAART had increased and that the age 
of initiation had decreased but the number of children initiating HAART with severe 
disease had remained high (Davies et al, 2013). The authors stated that even though the 
number of children accessing HAART had increased, improvement was still required in the 
field of early diagnosis and treatment. In 2013, the WHO guidelines stated that HAART 
should be initiated for all children under the age of five years regardless of clinical stage, 
with only older children needing to meet the immunological criteria (Donald et al, 2015; 
Vreeman et al, 2015) and this WHO recommendation has been further revised in 2015, 
which states that HAART should be administered to all children less than ten years as well 
as adolescents between the age of 10 and 19 years irrespective of stage of disease or 
21 
 
CD4 count. Once these guidelines are being followed in resource-limited settings, the 
number of children on HAART will sharply increase (Kukoyi, 2016).  
In South Africa, the three stages of HAART treatment involve the first, second and third 
line regime (Appendix 15). All infants under the age of three or less than 10 kg use a 
combination of Abacavir (ABC), Lamividine (3TC) and Lopinavir or Ritonavir (LPV/r).  
Alternatively, LPV/r can be replaced with Efavirenz (EFV) (Department of Health 2015).  
Failure of this combination will cause the patient to move on to the second regime of drugs 
which include ABC, 3TC, LPV or Stavudine (D4T) in place of ABC (Department of Health 
2015). 
Growth failure was a hallmark sign of disease progression and an independent risk factor 
for death (Arpadi, 2005). However, the initiation of HAART not only decreases mortality but 
has also improves growth parameters in HIV infected children. In the pre-HAART era, HIV 
infected children were shown to have significantly lower weight and height for age 
compared to normally developing children (Shead et al, 2010) and progressive stunting 
was more common than wasting (Arpadi, 2005). This was attributed to persistent infection, 
protein breakdown and malnutrition (Shead et al, 2010).  
 In a longitudinal study to investigate the effect of HAART on growth in South Africa, 
Feinstein et al (2012) assessed 2399 children between 2004 and 2008. Measurements 
were taken at treatment initiation and again two years later. At baseline, 71% presented 
with growth failure. At two year follow up, 81% and 64% had attained normal weight and 
height respectively. Younger children and children with less severe growth failure were 
more likely to have catch-up growth after HAART initiation. This was supported by Sutcliffe 
et al (2011) and Weigel et al (2010) who investigated the effect of HAART on growth in 
children in sub-Saharan Africa. In both studies baseline scores showed HIV infected 
children were significantly underweight and stunted compared to age-matched peers. 
HAART resulted in significant improvement in these growth parameters but they did not 
reach normal growth after two years of treatment. Unlike Feinstein et al (2012), Weigel et 
al (2010), found that the severely undernourished and stunted children benefitted the most 
from HAART with regards to catch-up growth. A high viral load was initially associated with 
poor growth in children and infants with HIV however no association was found between 
the two once HAART was initiated (Arpadi, 2005). 
Although HAART has been shown to improve mortality, it also has adverse effects. The 
interaction between the virus, HAART and inflammation can lead to various multi-organ 
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metabolic conditions (Donald et al, 2014b; Stanley and Grinspoon, 2012). NRTI’s are 
associated with peripheral neuropathy and lipodystophy as a result of mithochondrial 
dysfunction. PI’s are associated with dyslipidemia, osteoposrosis and impaired glucose 
homeostasis (Arpadi et al, 2013; Schiller 2004). Changes in lipid and glucose metabolism 
are prevalent in older children, adolescents as well as 20-80% of adults receiving HAART 
(Arpadi et al, 2013; Schiller 2004). Fat redistribution results in lipoatrophy peripherally and 
lipohypertrophy centrally around the trunk. This together with insulin resistance increases 
the risk for cardiovascular abnormalities which in turn can result in a sedentary lifestyle 
(Miller et al, 2010; Schiller, 2004). Cardiovascular disease is the leading cause of mortality 
among HIV infected adults in developed countries (Somarriba et al, 2013). There is also a 
high risk for cardiovascular abnormalities in children and adolescents but the extent to 
which it impacts morbidity and mortality is unclear (Miller et al, 2010). 
 Other organ systems that can be affected adversely are gastrointestinal e.g. nausea and 
vomiting; musculoskeletal e.g. osteopaenia; neurologic e.g. peripheral neuropathy; renal 
e.g. nephrotoxicity; dermatological and haematological. These side effects are reported in 
50% of adult patients and are responsible for poor compliance with treatment regimens 
(Donald et al, 2014b; Schiller 2004). 
2.4.4 Viral Load   
Viral load (VL) is defined as the number of viral particles (HIV virus) present in the 
bloodstream of the organism. It is used to monitor the effectiveness of antiretroviral 
therapy, detect treatment failure and guide changes in treatment regimens. Optimal viral 
load should be below the level of detection as it indicates effective viral suppression 
(Rutherford et al, 2014).   
The definition of virological treatment failure, as defined by WHO, is plasma viral load 
levels above 1000 copies/ml. This should be based on two viral load measurements after 
three months of HAART. The rate of treatment failure in HIV infected children in sub-
Saharan Africa is between 13 to 44%. Therefore regular VL monitoring is important to 
determine the effectiveness of first line HAART management in children (Kukoyi et al, 
2016). 
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2.5 HIV Encephalopathy (HIVE) 
Vertical transmission leads to an increased risk of irreversible brain damage, intracerebral 
calcifications, microcephaly and developmental and cognitive impairment (Walker et al, 
2013; Hilburn et al, 2010). This form of HIV-associated neurological disease in children is 
known as HIV encephalopathy (HIVE). 
2.5.1 Definition 
Early invasion of the CNS by the virus affects the developing brain and results in the most 
common HIV related CNS complication - HIV encephalopathy (Donald et al, 2015, 
Vreeman et al; 2015). HIVE was included as an AIDS-defining illness in children in 1987 
(Patel et al, 2009; Smith et al, 2008). It is described as the failure to attain or a loss of a 
previously attained motor or cognitive milestone (Hilburn et al, 2010) and is often evident 
before there are any other significant signs of immunosuppression (van Rie et al, 2007). 
The WHO (2007) defines HIV encephalopathy as follows:  “at least one of the following 
progressing over at least two months in the absence of another illness:- 
1. Failure to attain, or loss of, developmental milestones or loss of intellectual 
ability 
2. Progressive impaired brain growth demonstrated by stagnation of head 
circumference 
3. Acquired symmetric motor deficit accompanied by two or more of the 
following paresis, pathological reflexes, ataxia, gait disturbances” (WHO, 
2007, pg 39) 
Brain computed tomography scan or magnetic resonance imaging should be 
performed to exclude other causes (WHO, 2007). 
“The CDC criteria for HIVE require at least one of the following to be present for the past 
two months in the absence of another illness: 
1. Loss of previously acquired skill 
2. Significant drop in cognitive test scores general to the borderline/delayed 
range, with functional deficits 
3. Cognitive test scores in the borderline/delayed range , with functional deficits 
(and no history of significant drop or previous testing available) 
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4. Significantly abnormal neurological exam with functional deficits (i.e. 
significant tone, reflexes, cerebellar, gait or movement abnormalities) 
5. Significant improvement in cognitive test scores over approximately a six 
month period associated with new treatment when baseline scores are in the 
borderline to delayed range, with or without significant brain imaging or 
neurologic abnormalities” ( Walker et al, 2013, pg e863). 
There are three sub-types of encephalopathy, namely: 1) subacute-progressive, 2) plateau 
encephalopathy and 3) static encephalopathy (Hilburn et al, 2010). Progressive 
encephalopathy is associated with neurodevelopmental and intellectual regression 
(Donald et al 2015; Hilburn et al, 2010; van Rie et al, 2007) and can be characterised by 
microcephaly (Smith et al, 2008). These children are stable for prolonged periods of time 
until they present with a gradual loss of previously obtained milestones. Plateau 
encephalopathy depicts a pattern whereby children do not progress nor do they show 
deterioration in their development for prolonged periods of time. Children who have been 
vertically infected usually present with static encephalopathy. In these cases there is no 
deterioration of attained milestones but they do have significantly delayed developmental 
and motor milestones (Donald et al, 2015; Hilburn et al, 2010).  The prevalence of HIVE in 
South Africa has been documented between 13 and 35% (Smith et al 2008) and can 
increase to 20-60% in untreated children (Donald et al, 2014a). 
2.5.2  Pathogenesis of HIVE 
The developing brain is more susceptible to early and more severe invasion of HIV 
compared to adults (Donald et al, 2015). HIV is able to enter the central nervous system 
(CNS) during pregnancy and this, results in damage to the developing brain (Whitehead et 
al, 2014). HIV invades the central nervous system via infected monocytes and 
macrophages that are able to cross the blood-brain barrier. HIV can also infect astrocytes 
and this is thought to be significant in paediatric HIVE as they are more susceptible to 
infection (Crowell et al, 2014; Hilburn et al, 2010; van Rie et al, 2007). Neuronal damage 
can occur due to an inflammatory response and these changes are associated with 
disruption of synapse formation which is closely correlated to neurocognitive deficits 
(Crowell et al, 2014). The most vulnerable areas in the brain include the white matter, 
basal ganglia and cells around the blood vessels.  Radiological findings have shown 
cortical atrophy and basal ganglia calcification and white matter lesions (Govender et al, 
2011; van Rie et al, 2007).   
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Abnormalities found in the white matter in children under the age of three months, are 
indicative of early CNS invasion. Furthermore, subtle white matter abnormalities indicate a 
combination of diffuse myelin loss, astroglial proliferation and an infiltration of monocytes 
and macrophages (Donald et al, 2015). Magnetic Resonance Imaging (MRI) scans were 
taken of 44 children who were part of the CHER trial and suspected of having neurological 
complications. Thirty-four participants were from the early HAART initiation group. The 
mean age at which the scans were taken was 31.9 months. A review of the scans showed 
that 50% of the children referred had white matter signal abnormalities in the frontal and 
parietal lobes. No correlation was found between these radiological findings and the 
developmental scores or viral load. This suggests that brain lesions can occur early and 
initiation of HAART at eight weeks of age may still be too late to prevent HIV from 
penetrating the CNS (Ackerman et al, 2014). 
HIV is neurotropic. There is rapid replication of the virus in the central nervous system 
which leads to early manifestation of severe physical and neurocognitive signs and 
symptoms. This neurological manifestation can occur before any other signs of 
immunosuppression that are associated with HIV (Donald et al, 2014b; Walker et al, 2013; 
Smith et al, 2008). 
Risk factors associated with HIVE include maternal and child immune status, high plasma 
viral load in infancy, high circulating monocytes, timing of infection, route of transmission 
and availability of early treatment (Donald et al, 2015; Hilburn et al,2010; van Rie et al, 
2007). The risk of developing HIVE is also higher if the maternal viral load at the time of 
delivery is high and if children have a high plasma viral load in infancy (van Rie et al, 
2007). 
HIV infected children are also predisposed to opportunistic infections that affect the CNS 
such as meningitis. As a result, neurological manifestations of HIV may be complex 
(Donald et al, 2014b; Smith et al, 2008). In resource-limited settings, environmental factors 
contribute towards neurocognitive development. Poverty, malnutrition, altered family 
dynamics, poor maternal education, drug and alcohol abuse and prolonged illnesses will 
negatively impact both motor and cognitive development in children infected with HIV 
(Donald et al, 2015; Hilburn et al, 2010; van Rie et al, 2007). 
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2.5.3 Presentation of HIVE 
A major feature of encephalopathy is neurodevelopmental delay. These delays are seen in 
cognitive deficits like: impairment of memory, visual-spatial integration, executive function, 
language and speech deficits and general gross and fine motor deficits (Donald et al, 
2015; Vreeman et al, 2015; Whitehead et al, 2014; Hutchings and Potterton, 2013; 
Potterton et al, 2013; Govender et al, 2011; Potterton et al, 2010; Shead et al, 2010; van 
Rie et al, 2009; Bailieu and Potterton, 2008). In South Africa various studies have been 
conducted to determine the extent of delay and the effect of HAART on 
neurodevelopmental delay. These will be presented chronologically from infancy to 
adolescence. 
  2.5.3.1 Neurodevelopmental delay in infancy 
The roll-out of HAART began in 2004 in South Africa. As discussed previously during this 
period, children only received treatment if they had a CD4 count of less than 15% or an 
incident of opportunistic illness. The percentage of motor, cognitive and language delay in 
infants who did not receive HAART and were severely immunocompromised was 97.5% 
for motor and cognitive delay and 82.5% for language delay (Bailieu and Potterton, 2008). 
All infants were assessed using the Bayley Scales for Infant Development second edition 
(BSID II) and motor delay was the most severely affected. Shead et al (2010) investigated 
the extent of delay in institutionalised infants whose family circumstances were not 
conducive to their well-being. These subjects were not on HAART and results were 
compared to HIV uninfected infants that were also institutionalised. Similar to the previous 
study, the HIV infected group were significantly delayed in motor and cognitive areas 
compared to the HIV uninfected group and motor delay was more severe. In this study 
both groups showed a delay in mental development which could have been a result of 
inadequate mental stimulation as a result of poor living circumstances (Shead et al, 2010). 
Children in institutional care had a better motor performance than those in foster care 
when assessed using the Peabody Development Motor Scale, but in both places children 
with HIV performed worse than HIV uninfected children. In this study, all HIV infected 
children were receiving treatment and after six months showed improvement. This was 
attributed to stimulation provided by volunteers at these institutions (Jelsma et al, 2011). 
With increasing access to HAART, the results from the CHER trial in South Africa showed 
that early initiation of treatment (< eight weeks) had better morbidity and mortality 
outcomes than deferred initiation. As a continuation of this trial, Laughton et al (2012) 
assessed the neurodevelopmental outcomes using the Griffiths Mental Developmental 
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Scales (GMDS) in infants receiving early HAART (< three months) and deferred HAART     
(> three months). Infants receiving early treatment scored better than those who received 
deferred treatment. The early treatment group had better scores for speech and hearing 
and eye-hand coordination. When compared to HIV uninfected children, the early 
treatment group scored similarly except in the locomotor scale. The authors provided 
strong evidence for the benefits of early treatment on neurodevelopmental outcome 
(Laughton et al, 2012). 
In order to determine whether these benefits had a sustained effect over time, the 
development of infants on treatment needs to be assessed longitudinally. Twenty-seven 
HIV infected infants and 29 HIV exposed but uninfected infants were assessed using the 
BSID III prior to initiating HAART, at three months and again at six months. All HIV 
infected subjects were on a HAART regimen. The results for cognitive development 
showed that thirty percent of HIV infected infants had delay at baseline but by the second 
visit there were no significant differences between the groups. In terms of language, 45% 
had delay and the HIV infected infants performed worse than the HIV uninfected infants. 
Forty percent of HIV infected infants had motor delay by the second assessment and this 
increased from 29.6% at baseline. The authors postulated that there may be residual 
effects of the virus on muscle growth and strength (Whitehead et al, 2014).  A similar study 
conducted in Zimbabwe, also found that HIV infected infants presented with 64.29% 
cognitive, 60.71% language and 53.57% motor delay compared to HIV uninfected exposed 
infants. This study had a larger sample size of sixty HIV infected and thirty-two HIV 
uninfected but exposed infants (Hutchings and Potterton, 2013). 
The above studies have shown that cognitive, motor and language delays in infancy have 
decreased since HAART exposure has increased in South Africa, but they are still 
prevalent. Therefore it can be assumed that these problems may persist as the child 
moves forward into the school going phase. The next section will discuss the delays that 
children may experience in this phase. 
2.5.3.2 Neurodevelopmental delay in pre-school and school-going children 
Three studies have focussed on the neurodevelopment preschool age children between 
three and six years old in Africa and South Africa (Potterton et al, 2016; Lowick et al, 2012; 
van Rie et al, 2009). During this stage there is substantial amount of cognitive, language 
and speech development. Children refine their gross motor skills and start developing fine 
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motor co-ordination (CDC, 2016). Delays in this age group can have a negative impact on 
play and participation.  
The two more recent studies conducted in South Africa, evaluated the development of HIV 
infected pre-school children using the GMDS as an outcome tool. In both studies children 
had access to early HAART and were medically stable. The subjects showed good 
virological control and HIV management.  Lowick et al (2012) compared HIV infected 
subjects to HIV uninfected subjects from the same community and Potterton et al (2016) 
only assessed HIV infected children. Both studies found HIV infected children were 
delayed in all facets of cognitive performance. Lowick et al (2012) found that ninety 
percent of the infected group had severe cognitive delay with 46.7% showing signs of 
mental handicap. The percentage of delay was better (55.8%) in the study done by 
Potterton et al (2016) and this could be as a result of early ARV initiation in this group of 
children. However, despite early initiation there was still prevalence of delay. Hearing and 
speech were the most affected in both studies. These results were similar to an earlier 
study conducted in the Democratic Republic of Congo. The authors used the BSID II, the 
Peabody Developmental Motor Scale (2nd edition) and the Snijders-Oomen Nonverbal 
Intelligence Test as outcome measures. After a year of HIV treatment motor scores 
improved but cognitive scores didn’t improve as significantly compared with baseline data. 
The motor improvement was attributed to improved general health and access to 
nutritional programs. The lack of cognitive gain was attributed to negative living 
environment, poverty and illness of the parent (van Rie et al, 2009). 
As compared to infants who showed more severe motor delay, pre-school children appear 
to show more cognitive delay. Pre-school children with delay are then expected to enter 
into the formal school system where greater demand will be placed on them both 
physically and cognitively. 
Visual and auditory performance, attention, visual-spatial processing, problem solving, 
planning, manual dexterity and speed and agility were assessed in HIV infected and 
uninfected children over the age of six years in Uganda. All HIV infected participants were 
not receiving treatment but had CD4 counts over 15% or greater than 350cells/µL. This 
study was done to evaluate the neurocognitive function of school-aged children. HIV 
infected children scored significantly lower in visual modules, attention, processing and 
problem solving as well as motor function. The authors postulated that these significant 
motor and cognitive deficits could be prevented or reversed with early initiation of 
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treatment (Ruel et al, 2012). These results are supported by Smith et al (2008) who 
assessed the neurocognitive function of the first children who accessed HAART treatment 
in 2002 and 2003. Deficits in cognitive, motor and language areas persisted after six 
months of treatment. They also advocated for early HAART initiation (Smith et al, 2008). 
Walker et al (2013) assessed the neurocognitive function of HIV infected children with the 
diagnosis of HIVE compared to those without HIVE in Jamaica, which is also regarded as 
a developing country. A small sample of fifteen subjects per group with a mean age of 8.7 
and nine years respectively, were assessed using tests that measured intelligence, visual 
and auditory memory, attention and fine motor coordination. Children with HIVE presented 
with the following: delayed milestones, hyperreflexia, spasticity, microcephaly, 
quadruparesis, diplegia, poor behaviour, milestone regression and poor learning.  Other 
neurological abnormalities such as learning deficits, delayed milestone, isolated 
hyperreflexia and isolated leukencephelopathy were found in non-encephelopathic 
children. Children with HIVE performed significantly worse in all areas tested. Their 
prevalence of HIVE was 23.3% (Walker et al, 2013). 
Besides motor and cognitive delays, behavioural problems may also be a concern in this 
population of children which could negatively impact learning. The Abberant Behaviour 
Checklist was completed by parents as part of study to determine the extent of 
neurological conditions affecting HIV infected children. Parents of 39 out of 63 children 
reported behaviour problems which ranged from hyperactivity (20%), psychosomatic 
(28%), conduct (10%) and anxiety (8%). The authors postulated that this could be as a 
direct result of the virus on the frontal cortex and basal ganglia (Govender et al, 2011). 
HIV infected children experience motor, cognitive and language delays from infancy 
through to school going age. Behavioural problems start becoming more prevalent during 
the school going years. Furthermore, those presenting with HIVE perform worse in these 
areas compared to children without HIVE. These deficits are not reversed with HAART 
indicating that there may have been irreversible CNS damage early on, ongoing neuronal 
injury due to inflammation, neurotoxic effects of HAART or poor CNS penetration leading 
to ongoing viral replication (Crowell et al, 2014; Smith et al, 2008). Children with HIV have 
a greater survival rate and thus it is necessary to also understand how these delays impact 
them in their teenage years. 
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2.5.3.3 Neurodevelopmental delay in adolescence 
Adolescence is regarded as a period when individuals learn to be more independent and 
start to develop their own identity. Their ability to think abstractly and refine their cognitive 
abilities improves during this time. The brain doesn’t grow in size during this time but 
matures through increased myelination and organisation of the frontal lobes. This area is 
important for cognition and executive function. As with infancy, this maturation is 
influenced by genetic and environmental factors (Laughton et al, 2013). This is also a time 
for rapid physical growth and pubertal development. HIV infected adolescents have 
delayed entrance into puberty (Vreeman et al, 2015) and have to deal with stigma that 
may be associated with slow growth compared to peers (Lowenthal et al, 2014). 
A child born in 2004 or 2005 would be twelve or thirteen in 2016 and just entering 
adolescence. Due to the variation of treatment policies when these children were born 
there is a great variability in the amount of HAART exposure that they have had. Some 
may have started treatment early if they fulfilled the CDC criteria at the time, some may 
have started after the diagnosis of HIVE and some may have been initially ARV naïve. 
One review article highlighted the neurodevelopmental concern of HIV infected 
adolescents. There was a paucity of literature with regard to this age group (10-25 years) 
in developing countries. The author cautioned against assuming that results from studies 
conducted in the developed world can be applied to developing countries due to 
differences in treatment policies, economy and environment. A review of literature globally 
showed that HIV infected children and adolescents performed poorly in cognitive 
assessments and in specific executive function tasks like memory and attention compared 
to HIV uninfected counterparts. Language and hearing were was also poor thereby 
affecting literacy and academic success. Learning deficits result in 27-33% of children and 
adolescents needing special education, 51% having repeated at least one grade and 15% 
having repeated two or more grades. Pre-existing motor difficulties continue to pose 
challenges into adolescence (Laughton et al, 2013). 
Studies from the USA report 25% prevalence of psychiatric problems in HIV infected 
children and adolescents. This was highly correlated to negative coping skills and poor 
neuropsychological functioning. In resource-limited settings the prevalence of attention 
deficit hyperactivity disorder was 28.6%, anxiety 24.3% and depression 25%. There were 
a limited number of studies in this setting but Efivarenz was associated attention and 
hyperactivity problems in children with HIV (Donald et al, 2014b). 
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 These behavioural problems have an impact on compliance with HAART and risk-taking 
behaviours like promiscuity and drug abuse (Laughton et al, 2013). Furthermore, HIV 
infected adolescents are also at higher risk for psychosocial issues as they may have to 
deal with death of parents or siblings and may be responsible for running the household 
themselves (Lowenthal et al, 2014). The authors concluded that the impact of HIV on 
adolescents is complex and not well understood. Therefore there is a need for further 
research in this area especially in developing countries where HIV is more prevalent.  
All evidence presented shows that infants, children and adolescents with HIVE perform 
poorly with regards to cognitive, language and hearing, behavioural and motor functions. 
They also present with significant neurodevelopmental delay compared to HIV uninfected 
peers. These delays remain despite children having early access to treatment. As children 
get older, there is a greater association with more subtle and specific cognitive impairment 
as well behavioural and psychological problems (Donald et al, 2014b) and this has a 
profound impact on learning and scholastic achievement. This suggests that CNS damage 
has occurred early on despite participants having good viral control (Donald et al, 2015). A 
comprehensive neurodevelopmental and behavioural assessment needs to be carried out 
to accurately detect delays (Govender et al, 2011). Unfortunately, in resource-limited 
settings, HIVE remains a frequently undiagnosed problem in clinical practice (Donald et al, 
2015; Govender et al, 2011). 
2.5.4 HIVE and spastic diplegia 
Neurological signs like abnormal rigidity of limbs and abnormal postural tone are not very 
different from what is observed in children with CP (Tardieu, 1998; Mintz, 1996). At the 
Red Cross Children’s Hospital in South Africa, HIVE is the most common primary 
neurological disorder of HIV infected children. Donald et al (2015), set out to determine the 
descriptive profile as well as the challenges of management of children attending the HIV-
Neurology clinic. Their study included 87 children, between the ages of two and nine who 
fulfilled the criteria for HIVE. Each participant underwent a medical and physical 
examination. Their findings indicated that 80% of the children had delayed walking, 75% 
delayed speech, 48% presented with microcephaly and 63% presented with spastic 
diplegia. There was no statistical difference in the age of commencement of HAART and 
children with and without microcephaly. However, this was approaching significance 
(p=0.06) in those with and without diplegia (Donald et al, 2015).  
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Similarly Govender et al (2011) assessed 78 HIV infected children with a mean age of five 
years at the Groote Schuur and Red Cross Children’s Hospitals in South Africa. Subjects 
underwent a general and neurological examination. In their study 59% of subjects had 
abnormalities on neurological examination. These included HIVE, global pyramidal tract 
signs, cerebrovascular events, diplegia, quadraparesis, proximal weakness, distal 
weakness and epilepsy. HIVE was statistically more common (p=0.012) in patients that did 
not receive antiretroviral therapy (Govender et al, 2011).  
Diplegia is a known classification of CP and is also one of the residual impairments of HIV 
encephalopathy (Donald, 2015; Langerak et al, 2014; Govender, 2011). In order to 
differentiate between the two Langerak et al, (2014) assessed children with spastic 
diplegia as a result of HIV encephalopathy in order to present a first description of gait and 
physical status. Fourteen children between the age of four and ten years old with a 
diagnosis of HIVE and diplegia were assessed. Demographic, medical, socio-economic 
and anthropometric information was collected. In addition to this, children were classified 
according to the GMFCS and Functional Mobility Scale (FMS). Gait was analysed using 
Three-dimensional Gait Analysis (3DGA) and body function parameters of muscle 
strength, tone, selective motor control and contractures were also assessed. Their results 
showed two distinct patterns of gait which could not be classified in the typical spastic 
diplegic CP gait that was described by Rodda et al, (2004).  Group one walked with a gait 
pattern close to the pattern of a typically developed person, they had mainly increased 
plantarflexor tone and showed a decrease in muscle strength. Group two had a more 
pathological gait pattern. This was mainly noted with persistent knee flexion and ankle 
plantarflexion through the gait cycle. Their tone increased from proximal to distal and was 
higher than group one while muscle strength was significantly lower than group one. 
HAART initiation was significantly earlier in group one (6.7months) compared to group two 
(11.2 months). Limitations of this study include a small sample size as well as the lack of a 
comparative control group. The authors have suggested that diplegia as a result of HIVE 
may be underreported and they recommend that further studies are required to understand 
the underlying pathology and natural progression of this condition (Langerak et al, 2014). 
These studies suggest that HIVE may result in a presentation similar to that of CP 
diplegics but to date there are no studies that have documented the similarities and 
differences in their presentations. 
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2.5.5 Effect of HAART on HIVE 
HAART needs to cross the blood-brain-barrier in order to inhibit or delay HIV replication in 
the CNS. Antiretroviral medications are given a score based on its ability to effectively 
penetrate the CNS. High CNS penetrating drugs like zidovudine and nevirapine have a 
score of four. These regimens were associated with a 41% reduction in the incidence of 
HIVE (Patel et al, 2009). Several studies have shown that there has been a decline in the 
incidence of HIV encephalopathy since the increased use of HAART (Whitehead et al, 
2014; Patel et al, 2009; van Rie et al, 2009).  
In the USA, HAART has decreased prevalence of HIVE from 35-50% to less than 2% 
(Donald et al, 2015; Vreeman et al, 2015). Viral suppression before the age of five years 
was associated with positive neurocognitive outcomes in school-going children. Further 
studies are required to determine if these benefits persist through adolescence (Crowell et 
al, 2015). Early initiation of HAART results in improved neurodevelopmental outcomes 
compared to deferred initiation (Whitehead, 2014; Laughton et al, 2012). However in 
developing countries prior to 2010, HAART initiation is often delayed beyond infancy as it 
was only initiated if the CD4 count was below 15% or if there was evidence of an 
opportunistic illness, therefore HIVE still remains a frequent problem ( Donald et al, 2015 ). 
HAART improves some of the neurological sequelae of HIVE, however, it does not reverse 
the damage that has already occurred (Vreeman et al, 2015; Laughton et al, 2013; Walker 
et al, 2013; Govender et al, 2011; Smith et al, 2008). Neurological, behavioural and 
cognitive deficits may still persist (Govender et al, 2011; Smith et al, 2008; van Rie et al, 
2007). Many studies in both resource limited as well as resource rich settings have 
advocated for early HAART initiation in order to minimise neurodevelopmental 
consequences ( Whitehead et al, 2013; Laughton et al, 2012; van Rie et al, 2009; Patel et 
al, 2009; Smith et al; 2008). Early HAART initiation before three months of age is 
associated with a more favourable neurological outcome (Donald et al, 2014b). One also 
needs to consider the impact the environment, access to resources, the effect of 
opportunistic infections, nutrition and poverty can have on the child’s neurodevelopment 
(Donald et al, 2015; Donald et al, 2014b; Laughton et al, 2013; van Rie et al, 2009; Smith 
et al, 2008).  
In a review of the physical and psychological effects of HIV infection and treatment on HIV 
infected children, Vreeman et al (2015) noted that the potential neurotoxic effects of 
HAART on the developing foetus in utero are unclear although acquisition of HIV in utero 
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is associated with more severe neurocognitive function (Crowell et al, 2014). Medication 
that has high CNS penetrating qualities may be able to control HIV replication in the CNS 
but it may also increase the risk for neurotoxicity. The mechanism by which this occurs is 
through metabolic derangement associated with the medication, mitochondrial toxicity 
associated with NRTI’s and proteosomal dysfunction associated with PI’s (Crowell et al, 
2014). Currently the benefits of good CNS viral control must be weighed up against the 
effect of neurotoxicity. There is a strong need for research to investigate neurotoxic effects 
of HAART as well as to investigate if its benefits will continue into adolescence and 
adulthood (Vreeman et al, 2015). 
2.5.6 Muscle Strength in HIV 
During the acute phase of HIV, there is a loss of muscle protein (Hsu et al, 2005). Impaired 
muscle strength in children with HIV has been described in several studies where gross 
motor development is impaired or delayed (Langerak et al, 2014; Govender et al, 2011; 
Miller et al, 2010). 
In children normal muscle strength is required to play and explore the environment and 
therefore enhance normal development. Skeletal muscle represents 50-54% of lean body 
mass (LBM). A combination of malnutrition and abnormal endocrine function in HIV affects 
the body’s protein turnover. There is an increased protein demand due to inflammation 
from the virus and inadequate protein intake and absorption results in a loss of LBM. This 
is observed as muscle wasting and is associated with decreased muscle strength 
(Dudgeon et al, 2006; Grinspoon and Mulligan, 2003). Peripheral fat loss and increased 
central fat redistribution is an adverse effect of HAART. It can result in increased fat in the 
muscle tissue thereby affecting the force that can be generated by the muscle (Vreeman et 
al, 2015). This predisposes HIV infected children to increased cardiovascular and 
metabolic dysfunction which can lead to a sedentary lifestyle (Miller et al, 2010; Grinspoon 
and Mulligan, 2003).  
Many studies have investigated the effect of HIV, HAART and strengthening programmes 
on strength in adults as compared to very few in children.   
Humphries et al (2014) conducted a pilot study to investigate the muscle strength of 
children, between the age of four and eight years old, infected with HIV. The muscle 
strength of HIV infected children receiving HAART and not receiving HAART were 
compared with those of normally developing children. None of the subjects in this study 
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were diagnosed with HIVE. These results showed that the group not receiving HAART was 
significantly stronger than the group receiving HAART.  Both these groups still displayed a  
50% decrease in muscle strength compared to typically developing children. However the 
group receiving HAART were more severely immunocompromised and qualified for the 
CDC criteria for HAART initiation. The non-HAART group had not yet met this criteria and 
therefore they could have been stronger.  This study suggests that further testing is 
required to determine if HAART negatively impacts muscle strength and that a 
comprehensive values of normative muscle strength in children needs to be established.   
Physical fitness, strength and anaerobic power were investigated in HIV infected children 
and adolescents by Somarriba et al (2013), Ramos et al (2012) and Miller  et al (2010). 
The first study compared muscle strength, flexibility and cardiorespiratory fitness while the 
second study compared the muscle strength and anaerobic power of HIV infected children 
and adolescents to an uninfected control group. Both studies had small sample sizes of 45 
and 14 respectively. Somarriba et al (2013) found the HIV infected group to have less 
cardiorespiratory fitness and strength compared to the healthy control group while Ramos 
et al (2012) found the HIV infected group to have the same strength as the control group 
but decreased anaerobic power. Anaerobic power is required to complete daily, 
recreational or sports tasks efficiently (Ramos et al, 2012). Similar to Humphries et al 
(2014), Somarriba et al (2013) found that increased duration of HAART and increased 
body fat independently and negatively impacted on physical fitness. Fat redistribution and 
mitochondrial toxicity occur with increased exposure to NRTI’s and PI’s. This impact on 
mitochondrial function affects energy distribution to skeletal muscle thereby affecting 
strength and exercise capacity (Somarriba et al, 2013). 
Muscle strength, length and cardiorespiratory fitness improved with twenty-four supervised 
hospital exercise sessions which included aerobic exercises, resistance training and 
stretching. Of these measures, the greatest improvement was seen in strength. This 
exercise program also had a positive impact on lean body mass. Only seventeen HIV 
infected children and adolescents (mean age 15years) participated in this study. They also 
completed unsupervised home exercise program after completion of the hospital program. 
Follow-up assessment after seventeen weeks showed that there was no significant 
change and participants were able to maintain strength and fitness with a home program. 
This was a pilot, feasibility study and it is recommended that a larger study should be 
conducted (Miller et al, 2010). 
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Increasing protein intake as well as muscle strengthening programmes, have been found 
to be effective in decreasing muscle wasting and improving muscle strength (Miller et al, 
2010; Dudgeoun et al, 2006; Grinspoon and Mulligan, 2003).   
In summary, HIV infected children who were exposed to the virus during a period of rapid 
brain development may present with HIVE. They have been and will be exposed to the 
virus as well as the medication throughout their life and while HIV is no longer a life-
threatening illness, the long term complications are more prevalent. Motor, cognitive, 
behavioural and language deficits may persist and will need to be managed by a multi-
disciplinary team to give children the best chance possible for future success and quality of 
life.  
 
2.6 Outcome measures and measuring devices 
Assessment tools were selected to assess body structure and function (muscle strength 
and tone), activity (gross motor function) and participation (mobility in a community setting) 
in children with spastic diplegia. This is accordance with the International Classification of 
disability, functioning and health (ICF) framework which was developed by the WHO for 
the management of persons with disability. The aim of the ICF is to provide a framework 
that is internationally recognised and thereby gives health professionals a common 
language by which to describe patient’s disabilities and needs. The framework breaks 
down the patient’s disability into the following components: body structure and function, 
activity, participation, personal and environmental factors. Body structure and function 
describes the anatomical parts of the body and physiological body systems. Activity refers 
to the ability of the individual to execute a task while participation refers to the involvement 
of the person in life situations (Franki et al, 2012). 
2.6.1 Gross Motor Function Measure (GMFM) 
The GMFM is the gold standard outcome measure used by healthcare professionals to 
measure gross motor function in children with CP. It is a criterion- referenced based 
observational tool that was developed to assess children with CP, from the age of five 
months to 16 years (Russell et al, 2000). It is widely used by clinicians to measure change 
over time as well as change related to an intervention (Altoaibi et al, 2014). The first 
edition of the GMFM was published in 1990. 
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The GMFM-88 is the original measure testing 88 items over five dimensions. These items 
are organised in a way which reflects normal developmental milestones (Alotaibi et al, 
2014). These dimensions are: a) lying and rolling (17items), b) sitting (20items), c) 
crawling and kneeling (14items), d) standing (13items) and e) walking, running and 
jumping (24 items). Observation of these items enables the examiner to have a clear 
understanding of how much (quantity) the child can do rather than how well (quality) they 
do it. Each Item is scored on a four-point ordinal scale (zero=does not initiate, 
one=initiates < 10% of activity, two=partially completes 10 to <100% of activity and 
three=completes). Any item that the child is unable to or unwilling to do is given a zero 
rather than unachieved. This does not accurately reflect the child’s ability.  For each item 
the child is allowed a maximum of three attempts. Scores for each dimension are 
calculated, averaged out and converted into a percentage. The difference in points 
between GMFCS levels differentiates whether a child is able to roll, sit, crawl and walk 
(Palisano et al, 2000). The limitation of this tool is that it can take long to administer and it 
has a nominal scale. This means that the there is no set interval between different items 
on the scale making it difficult to interpret change in the scores (Russell et al, 2000). 
In order to improve the interpretability and clinical usefulness of the GMFM, Russell et al 
(2000) applied the Rasch analysis to the GMFM. This helped to identify 66 items from the 
original 88 that form a unidimensional, hierachial scale.  The advantages of using the 
GMFM-66 are that it takes less time to administer, items are arranged in the order of 
difficulty and the conversion from percentage to interval scaling has improved the 
interpretability of the total score. This provides the clinician with more information which is 
useful for goal-setting.  
The Gross Motor Ability Estimator (GMAE) is a computer program that converts the 
GMFM-66 individual scores into an interval scoring system. The GMFM-66 has a high test-
retest reliability has been found to be a valid (intraclass correlation coefficient=0.99) and is 
able to detect change after an intervention (P < .0001). With the above mentioned 
properties the GMFM-66 is widely used during clinical research (Russell et al, 2000). 
 Several systematic reviews of outcome measures in children with CP have been 
conducted. The GMFM and Paediatric Evaluation of Disability Inventory (PEDI) were found 
to be valid and reliable with respect to responsiveness to change (Ketelaar et al, 1998), 
while the GMFM was found to have sound psychometric properties (Harvey et al, 2008). 
Debuse and Bruce (2011) also reviewed outcome measures for activity for children with 
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CP. Although they found the GMFM-88 and 66 to be appropriate for this group, they have 
highlighted a few clinical considerations that need to be taken into account. Firstly, both 
the GMFM-88 and 66 only examine gross motor function and therefore it should be used in 
conjunction with other outcome measures to provide a comprehensive assessment of the 
child’s activity and participation. Secondly, they only give an indication of the child’s 
performance in a test environment. It does not account for the child’s motor responses in 
their normal environment. In addition to this, the following considerations need to be made 
when using the GMFM-66: it has a floor effect in children with poor motor ability and a 
ceiling effect in children older than five years. 
Most recently Alotaibi et al (2014) also reviewed the efficacy of the GMFM-88 and 66 to 
detect change in gross motor function in children with CP. Twenty one studies fulfilled their 
inclusion criteria. The studies had a moderate to high methodological quality and covered 
a wide age range from 10 months to 16 years. They concluded that both these measures 
were able to detect significant clinical change in gross motor function for children with CP 
under the age of 17. It may be less sensitive for detecting change in children who are at 
GMFCS level IV and V compared to GMFCS level II and III. They had similar clinical 
considerations as Debuse and Bruce (2011) with regard to the ceiling effect and using 
additional outcome measures to provide a comprehensive assessment. 
The minimum clinically important difference (MCID) is the amount of change required for 
an observable clinical difference (Oeffinger et al, 2008). It is measured using effect sizes 
i.e. small effect sizes are not noticeable by the human eye, medium effect sizes are large 
enough to be noticed in normal observation and large effect sizes are obviously 
observable. MCID’s for medium and large effect sizes were established for the Dimension 
D and E by assessing ambulant children with CP. This means if a change in score 
exceeds the MCID it is likely that the change is clinically important. The reported MCID, for 
the GMFM, of a medium effect size is 0.8 and for a large effect size is 1.3. These values 
are important in assessing change over time (Oeffinger et al, 2008). 
2.6.2 Functional Mobility Scale (FMS) 
The Functional Mobility Scale (See Appendix 14) was designed to evaluate the mobility of 
children with CP at different distances. The clinician asks a few questions of the child and 
parent in order to develop a performance rating.  The scale rates the walking ability of the 
children at three different distances: 5m (at home), 50m (at school) and 500m (in the 
community). The completion of these distances is rated from one to six, with one indicating 
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that the distance is attained by the use of a wheelchair or buggy, and six indicating that the 
subject is independently mobile on all surfaces. The tool also takes into account crawling, 
and if the distance is not applicable (Graham et al, 2004). 
 
In a systematic review of available outcome measures for children with CP by Harvey et al 
(2008), the FMS was the only measure that took into consideration the different devices 
that a child with CP might use as well as looking at the child’s mobility in different 
environments. However, it concluded that further evidence of reliability was required.   
Harvey et al, (2010) investigated the reliability of the FMS for children with CP. Forty-four 
raters assessed 118 CP children with GMFCS levels I-IV. The raters included hospital and 
community-based physiotherapists as well as orthopaedic surgeons. Results showed that 
there is good inter-rater reliability of the FMS for children with CP over all three distances 
with the kappa coefficient being 0.87 for 5m, 0.92 for 50m, and 0.86 for 500m. It was 
concluded that the FMS can be used by clinicians to assess the mobility of children with 
CP. 
2.6.3 Modified Ashworth Scale (MAS) 
The MAS is a 6-point rating scale that is used to assess the resistance of a muscle to 
passive movement. The original Ashworth scale was a five point scale which rated the 
amount of tone felt as the limb was moved passively through its full ROM. Modifications 
were added to give additional information of how soon in the motion and how much during 
the motion the resistance was felt (Damiano et al, 2002). The MAS is the most frequently 
used scale in clinical practice to measure spasticity in children with CP and/or adults with 
an upper motor neuron lesion (Numanoglu & Gunel, 2012; Mutlu et al, 2008). There is a 
significant correlation between the MAS and GMFM-66 (r=0.64) (Ostenjø et al, 2004). 
Despite this, the reliability of the scale is questionable. 
Numanoglu & Gunel (2012) and Yam and Leung (2006),  investigated the intra-observer  
and the inter-tester reliability of MAS and the Modified Tardieu Scale (MTS) respectively in 
children with CP. Spasticity of elbow flexors, wrist flexors, hip adductors, hamstrings, 
gastrocnemius and soleus muscles were evaluated by one assessor using both scales. 
Intra class coefficient (ICC) was chosen as the test statistic for reliability. Good reliability 
was defined as ICC greater than or equal to 0.75 in both studies. The intra-observer 
reliability for MAS did not reach the acceptable ICC level of 0.75, while MTS reached this 
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level for most muscles. Both the MAS and MTS showed ICC values of less than 0.75. The 
researchers found that the distinction between the scores is dependent on range of 
movement (ROM) and this makes interpretation difficult especially in muscles that are 
shortened. Factors such as emotional state of the child and pain were given as possible 
explanations for low reliability scores. They concluded that although it is easy to administer 
and does not require equipment, it is based on subjective decisions and has poor intra-
rater and inter-rater reliability. Further studies were recommended to establish reliability 
(Numanoglu & Gunel, 2012; Yam and Leung, 2006).   
The inter and intra-rater reliability of the MAS in children with hypertonia was also 
investigated by Clopton et al in 2005. Seventeen subjects were initially examined by three 
to four testers. They were re-tested by the principal examiner within six to eight days. The 
following muscles were tested: elbow flexors, hip adductors, quadriceps, hamstings, 
gastrocnemius and soleus. Their results showed that hamstrings had good inter-rater and 
intra-rater reliability (ICC>0.75), while elbow flexors had only good inter-rater reliability.  
The gastrocnemius and soleus muscles had the lowest reliability scores. A possible 
explanation for this could there is a shorter lever arm and there is usually more limited 
range of movement. Similarly, hip adductors and quadriceps showed low levels of 
reliability but this could not be explained by the shorter lever arm theory. The decreased 
attention span of the children was noted as a limitation of the study. They also 
recommended that the 1+ score be used as a rating for clonus (Clopton et al, 2005). 
The reliability of both the Ashworth and the Modified Asworth scale in children with CP was 
investigated by Mutlu et al in 2008. They assessed 38 spastic diplegic children between 
GMFCS level I-III. Each child was assessed by three different therapists in two different 
sessions a week apart. The muscle groups tested were: hip flexors, hip adductors and 
internal rotators, hamstrings and plantar flexors with the knee extended. Scores were 
recorded for both the Ashworth scale and the MAS. The results indicated good interrater 
reliability for hamstrings and adductors and moderate reliability for hip flexors and 
gatrocnemius. Intra-rater scores ranged from poor to good with hip internal rotators 
showing the least and hip flexors the most reliability. In this study, MAS had higher intra-
rater reliability scores than the Ashworth Scale (Mutlu et al, 2008). 
2.6.4 Muscle strength and hand held dynamometry 
Isometric muscle strength is indicative of the force produced at a particular muscle length 
while isokinetic muscle strength indicates the force produced through a controlled 
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movement (Verschuuren et al, 2008). Clinically, muscle strength is usually assessed 
isometrically using manual muscle testing or a dynamometer. Manual muscle testing is 
subjective, uses an ordinal scale and is not sensitive to small or medium muscle strength 
changes (Verschuren et al, 2008). In order to objectively measure strength one would 
need to use a device that is shown to be valid and reliable.  
 
Furthermore, isometric muscle testing can be done using the ‘break’ or the ‘make’ method. 
In the ‘break’ method, a force is gradually applied by the examiner to allow the subject to 
recruit the maximum number of muscle fibres. In the ‘make’ method, maximal effort is 
exerted by the participant against a stationary force. The reliability of using these methods 
for muscle testing with a hand-held dynamometer (HHD) was assessed in children with 
CP. The inter-tester reliability results were questionable for both methods. The precision of 
the break test ranged from 22.2% in the hip to 35.3% for the hip and knee, while the 
precision of the make test ranged from 16.2% in the hip to 56.2% in the ankle (Vershuren 
et al, 2008). 
 
Dekkers et al, (2014) systematically reviewed the availability of instruments for the 
measurement of upper limb strength in CP children. The clinimetric properties of the 
measuring instruments in each study were assessed. Six different measurement 
instruments were studied namely,1) manual muscle testing, 2) the Jamar dynamometer, 3) 
a HHD, 4) an instrument based on muscle strength-torque sensors, 5) a computerised 
measurement tool using a strain gauge and 6) a modified sphygmometer. The review 
highlighted the paucity in the literature with regard to upper limb strength testing. None of 
the instruments were rated as “strong” or “moderate” for their level of evidence. In this 
study, the MicroFET2 dynamometer was reviewed. The positive characteristics of the HHD 
are that it is a small, relatively inexpensive, easy-to-use device. It had the property of being 
able to detect small changes. The assessor may have challenges in being able to 
appropriately stabilise the patient when using this device. They suggested that 
standardised HHD procedures should be developed for testing of CP children and that the 
MicroFET2 dynamometer has the potential to be reliable in measuring upper limb strength 
(Dekkers et al, 2014). 
A recent study by Willemse et al (2013) assessed the reliability of isometric lower extremity 
testing in CP children. They used a MicroFET HHD to measure isometric strength on two 
separate occasions. Fourteen children with GMFCS level I-III were assessed. The ‘make’ 
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test was used and three trials were measured for each muscle group. The muscle groups 
assessed were knee extensors and flexors, hip flexors and abductors and ankle plantar 
flexors. Results showed that averaging scores over two trials is the most efficient 
approach. Two trials on two separate occasions would also improve the measurement 
error. The small sample size was a limitation of their study but they were able to provide a 
design for measurement. They concluded that a HHD is reliable and sensitive to changes 
in isometric muscle strength in children with CP (Willemse et al, 2013).   
This is supported by an earlier study by Crompton et al, (2007) who found HHD testing for 
hip extensors in prone and ankle plantarflexors was unreliable.  They concluded that hand-
held dynamometry has acceptable reliability (ICC>0.70) for hip flexors, knee flexors and 
extensors, ankle dorsiflexors with stabilisation and hip extensors in supine. Their results 
are valid for spastic diplegic children with GMFCS levels I-III.  
HHD has been shown to have good test-retest reliability (Crompton et al, 2007) and fair 
inter-rater reliability (Vershuren et al, 2008). It is an affordable and portable method for 
testing muscle strength. 
2.6.5 Normative muscle strength data 
In order to determine whether muscle strength of children with CP or HIV is weak or 
strong, we need to compare it to normative data for children of a similar age. There have 
been very few studies that have investigated normative muscle strength in children namely 
Beenakker et al. (2001), Nyström Eek et al. (2006) and Macfarlane et al (2008). These 
studies have been analysed in Table 2.4 below.  
The subjects in all the studies were normal typically developing children.  All the 
researchers divided their samples into categories of age and gender.  This resulted in the 
maximum number of children per group to be 18 and the minimum number to be five.  
Torque was calculated by dividing the strength by the distance of the lever arm. It allows 
for better comparison over time and between subjects that are growing (Nyström Eek et al, 
2006).  Macfarlane et al (2008) also provided cut off values for muscle strength. These 
values can be used to identify muscle weakness in children between the ages of six to 
eight. 
 
Although these studies all measured muscle strength in typically developing children, there 
is great variability in the age range, the sample sizes when divided into gender and age 
groups as well as the methodology. They have all reported an increase in strength with 
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increasing age weight and height but their predictors for muscle force all differ. It is 
important to compare the strength of a child to a group of the same gender and age.   
 
Table 2.4 Comparison of three studies investigating muscle strength values in normally  
developing children 
 Beenakker et al 
2001 
Nyström Eek et al, 
2006 
Macfarlane et al, 
2008 
Age Group 4-16 years 5-15 years 6-8 years 
Number of subjects 270 149 154 
Device HHD (CT3001) HHD HHD (Micro FET II) 
Muscle groups 11 (upper and lower 
limb) 
12 (upper and lower 
limb) 
6 (lower limb) 
Muscle Strength Unit 
measurement 
Newton Newton meter (Torque) Newton meter and 
Pounds 
Type of Muscle 
testing 
Isometric- Break test Isometric – Make test Isometric- Make test 
Methodology Reproducible Reproducible Reproducible 
Finding related to 
age, weight and 
height 
Weight was the best 
predictor of force in 
boys. 
Weight and age were 
the best predictor of 
force in girls 
Strong correlation to 
age and weight up to 
the age of 12 
Increase in strength 
with increasing age, 
weight and height. 
Height was the 
strongest predictor in 
this group. 
Findings related to 
gender 
No significant gender 
differences in 11-13 
year old age group 
Boys were stronger 
after the age of 13 
No differences 
between gender 
Implications Individual muscle force 
values are provided but 
summed scores may 
be more useful when 
determining a pattern 
of weakness where 
there is pathology  
None noted Important to have a 
standardised 
procedure to minimise 
compensatory 
movements 
Limitations None noted None noted All measurements were 
taken by one therapist, 
therefore caution 
should be exercised 
when interpreting the 
generalisability and 
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intra-rater reliability of 
the values 
 
2.7 Conclusion 
Spastic diplegia as a result of CP and as a result of HIVE may result in impairments 
growth, cognition and motor development. Abnormal muscle tone and decreased strength 
and poor selective motor control may also be present. These impairments as well as the 
natural progression are well described in children with CP but there is a paucity of 
literature with regard to diplegia as a result of HIVE. They both occur as a result of 
damage to an immature brain but the pathophysiology is different. HAART has resulted in 
a large number of children with HIVE surviving and reaching adolescence. Therefore it is 
important to determine the similarities and differences between these two groups as it will 
assist in guiding future management of HIV infected children with diplegia. 
 
 
 
 
 
 
 
 
 
 
 
  
45 
 
CHAPTER 3- METHODOLOGY 
 
This chapter discusses the methodology that was used to conduct this research 
3.1. Study Design 
A cross sectional, quantitative study was conducted. A once-off assessment of function, 
muscle strength and tone was performed on participants by the researcher. 
3.2 Ethical Clearance 
Application for ethical clearance was made to the Human Research and Ethics Committee 
(Medical) of the University of the Witwatersrand and approval was granted prior to starting 
the data collection process. The study ethical clearance number is  M140936 (See 
Appendix 1). 
3.2.1 Permission to conduct research 
Permission to conduct research was granted by the research board of Rahima Moosa 
Mother and Child Hospital (RMMCH) and Chris Hani Baragwanath Academic Hospital 
(CHBAH) respectively (See Appendices 2 and 3). Participants and their parents or care 
givers were given information sheets with an attached consent and assent form prior to the 
beginning of the assessment (See Appendices 4 and 5). Written informed consent and 
assent (for children over the age of six) was obtained from the participant and his or her 
primary caregiver (See Appendices 6 and 7). 
3.2.2. Ethical Considerations 
Since this study included human interaction the rights of patient’s were considered. This 
was achieved by emphasizing the Patient’s Rights Charter. Informed Consent is a 
substantial ethical cornerstone of human research. This study fulfilled this criterion by 
attaching an information sheet and consent form which explained the purpose of the study 
and as well as a detailed explanation of the research procedure. Parents and/ or 
caregivers of the subjects were required to complete the consent form as well as the 
medical questionnaire. Additional information may be obtained from the hospital file.  
Furthermore, an assent form was given to all participants over the age of six with an 
explanation of the procedure. Participants over the age of six were required to sign the 
document as confirmation that they understood the study, and that their decision to 
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participate was completely autonomous.  Parents and participants had the right to 
withdraw from the study at any stage with no adverse consequences. For parents and 
participants who did not understand English, the forms and questionnaire were translated 
by the physiotherapy assistant who spoke the language.  
Any materials or information obtained during the study will remain anonymous. 
Confidentiality will be maintained at all times. This was achieved by excluding the use of 
any information that would allow the subject to be identified; such as photographic 
material, subject’s name and identification documents. Feedback of the assessment was 
provided to the therapists working in the clinic, by the researcher. The researchers and 
any other personnel that had an interaction with a participant in the study conducted 
themselves in a professional manner. Guidelines, as defined by the Health Professions 
Council of South Africa, were adhered to during the study. 
 
3.3 Location 
This study was conducted at Chris Hani Baragwanath Academic Hospital (CHBAH), 
Rahima Moosa Mother and Child Hospital (RMMCH) and two private physiotherapy 
practices in Johannesburg, Gauteng.  All assessments were done in the treatment gyms of 
the respective physiotherapy departments. These sites were chosen as they have a 
patient base from which subjects could be recruited.  
3.4 Study Population 
3.4.1 Sample Size 
In the absence of other available published data on the functional status of children with 
HIVE, the central limit theorem was used to calculate a sample size of 30 participants per 
group. This was a sample of convenience which was obtained consecutively.  
 
3.4.2 Inclusion Criteria  
Children were included to participate in the study if: 
 They presented with spastic diplegia 
 They presented with GMFCS level I-IV 
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 They were HIV positive or negative and willing to disclose their HIV status 
 They were between  the age of four to sixteen years 
 They were able to follow a two-step instruction  
3.4.3 Exclusion Criteria  
Children were excluded if: 
 They had botulinum toxin injections less than six months prior to testing 
 They had orthopaedic surgery less than one year prior to testing 
 They presented with diplegia but had an unknown HIV status 
 
3.5 Outcome Measures and Measurement Devices 
3.5.1 The Gross Motor Function Measure (GMFM) 
The GMFM is a standardised tool which is used to measure the gross motor function of 
children with CP from childhood to adolescence. This tool is seen as the gold standard for 
gross motor assessment in this population (Debuse & Brace, 2011). The GMFM-66 was 
used as it takes less time to administer, has interval scaling for improved interpretability 
and a computer scoring system compared with the GMFM-88. It has the properties of 
reliability, validity and responsiveness. It is also widely used for research purposes 
(Russell et al, 2000). The GMFM-66 measures the quantity of the child’s performance on 
the day rather than the quality.  
3.5.2 Functional Mobility Scale 
The Functional Mobility Scale (FMS) is used to classify functional mobility in children with 
CP. It takes into account the range of assistive devices that the child might use as well as 
their ability in different environments of home, school and community. It is a performance 
measure of the child’s walking ability over 5 meters, 50 meters and 500 meters. This scale 
has been shown to have good inter-rater children with CP with the kappa coefficient being 
0.87 for 5m, 0.92 for 50m, and 0.86 for 500m (Harvey et al, 2010).  
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3.5.3 The Modified Ashworth Scale 
The Modified Ashworth Scale (MAS) was used to measure the spasticity in the lower 
limbs.  
Spasticity is defined as the resistance of a muscle to passive stretch. The MAS is a clinical 
tool that is used to quantify a patient’s spasticity. This is done by applying a passive 
velocity-dependent stretch and rating the resistance. It is quantified on a 6-point ordinal 
scale (see Table 3.1) from zero to four. Zero indicates no increase in muscle tone and four 
indicates that the affected limb is rigid (Mutlu et al, 2008; Clopton et al, 2005).  
Table 3.1 Modified Ashworth Scale (Clopton et al, 2005) 
Grade Description 
0 No increase in muscle tone 
1 Slight increase in muscle tone, manifested by a catch and release or by minimal 
resistance at the end of range of motion when the affected part is moved in flexion or 
extension 
1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance 
throughout the remainder (less than half) of the ROM 
2 More marked increase in muscle tone through most of the ROM, but affected parts 
easily moved 
3 Considerable increase in muscle tone, passive movement difficult 
4 Affected parts rigid in flexion or extension 
 
3.5.4 Hand Held Dynamometer  
Lower and upper extremity strength can be measured objectively by using a hand-held 
dynamometer (HHD). The device contains a force transducer that enables measurement 
of isometric muscle strength when it is held rigid and perpendicular to the person’s body 
(Willemse et al, 2013). Accurate measurement of strength is important for identifying any 
impairment of strength. Willemse et al (2013) proposed that a HHD is reliable and 
sensitive to changes when being used to assess muscle strength in children with CP. 
 
In this study the the MicroFET 2 was used.  This dynamometer measures muscle strength 
as force, measured in Newtons.  The minimum force it is able to measure is that of 3.6 N, 
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the maximum force is that of 660N. Forces are measured in 0.8 N increments.  The 
dynamometer was manufactured by Hoggan Health Industries and certified on February 
19th 2007. Isometric muscle strength of upper and lower limb muscles was tested using the 
‘make test’ with a HHD.  
3.5.5. Viral Load 
Viral load monitoring is recommended as the preferred method to confirm and diagnose 
treatment failure by WHO (Kukoyi et al, 2016). Viral load information was available for all 
HIV infected participants in this study, therefore the most recent viral load was obtained. 
Viral load levels were obtained through the National Health Laboratory Services (NHLS) at 
CHBH and or through information found in the patients file. 
3.5.6 Anthropometric measurements 
Height and weight measurements were taken for each child.  The weight and height for 
each participant was converted into a standardised z-score using WHO Anthroplus 
software. This software is used to facilitate the application of the WHO Reference 2007.  
The WHO reference 2007 provides a reference for standard height-for-age (HAZ), weight-
for-age (WAZ) and BMI-for-age (BAZ) growth parameters for the age group five to 
nineteen years.  The data tables and charts cover the first to the 99th percentile and 
standard deviations from +3 to -3. WHO Anthroplus software is used to determine the 
percentile and z-score for each individual. Depending on the child’s age the software 
applies the WHO standards (children under 5) or the WHO reference (5 to 19 years) to 
determine the scores.  A z-score < -2.00 indicates that a child in stunted (HAZ) or 
underweight (WAZ) while scores beyond +3.00 or -3.00 represents extremes in nutritional 
status. 
3.6 PROCEDURE 
3.6.1 Recruitment 
A database of children with spastic diplegia was obtained from the physiotherapy 
departments of CHBH and RMMCH as well as the orthopaedic department of CHBH. All 
children who met the inclusion criteria were invited either personally or telephonically to 
participate in the study.  Appointments were scheduled for the assessment. Where 
possible, appointments were made to try to correspond with other clinic appointments. 
Participants and care-givers were reimbursed a value of R50.00 towards transport costs. 
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Total number of 
Participants= 64 
CHBAH 
                                                        
Database= 37  Total recruited=18                                  
Clinic Visits= 6  Total recruited= 10 
                         
Database=26   Total Recruited=15 
Clinic Visits=3 Total Recruited=9 
RMMCH Database= 10 Total recruited= 5 
 
 Database=8                    
Total recruited=7 
The researcher also attended the orthopaedic and neurology clinic at CHBH from the 
period March to October 2015 to recruit participants. Children who were attending the 
clinic and eligible for the study were invited to participate on the same day. Participants 
were consecutively recruited. The flow diagram below summarises this process. 
 
 
 
 
 
 
   
 
Figure 3.1: Summary of recruitment process 
Each participant and care-giver was given an information sheet (Appendix 4 and 5) 
explaining the purpose of the study, a consent form (Appendix 6) and an assent form 
(Appendix 7) to complete. All forms were available in English. Verbal translation was 
provided when required. All participants were given the right to refuse to participate in the 
study. 
3.6.2 Medical History 
Parents and/or caregivers were required to complete a questionnaire (Appendix 8) which 
provided the researcher with information regarding the child’s medical history. This 
included pregnancy and birth history, complications after birth, developmental milestones, 
medication, additional medical and surgical history, HIV status and management and care 
with regard to this. Additional information was obtained from the hospital file. The 
participants were placed into one of two groups based on their HIV status. 
3.6.3 Measurements 
All measurements as described below were conducted on all participants by the primary 
researcher. She had 14 years of physiotherapy experience on commencement of this 
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study and is trained in neurodevelopmental therapy. Willingness of the parent to disclose 
the HIV status of the participant was one of the inclusion criteria therefore the primary 
researcher was not blinded to the participants HIV status. All results were recorded on a 
data collection sheet (Appendix 9). 
 
1. Anthropometric measurements of weight and height were carried out. Participants’ 
height was measured in supine with their feet against the wall. It was measured in 
centimetres from the wall to the top of the head.  Their weight was measured in 
kilograms using a standing electronic bathroom scale. Height-for-age, weight-for-
age and BMI-for-age z scores were calculated using WHO Anthroplus Software.  
2. The GMFCS score was determined by the physiotherapist according to the GMFCS 
guidelines. 
3. The FMS was scored for each child according to care-giver report (See Appendix 
13). 
4. The GMFM-66 was completed according to the guidelines in the user manual 
(Gross Motor Function Measure (GMFM 88 & GMFM66) User’s Manual (2002)). 
Each child was given three turns to complete an item, as per the instruction manual 
and scores were recorded on the scoring sheet (Appendix 12).  The total score was 
calculated using the Gross Motor Ability Estimator (GMAE) program. Each 
dimension score from A to E was converted into a percentage out of a 100. 
5.  Muscle tone was assessed in supine using the Modified Ashworth scale. The 
following muscles were assessed bilaterally: hip adductors, hamstrings, soleus and 
gastrocnemius. Each joint was moved through its passive range of motion 3 times. 
The passive movements were done at approximately one second per movement 
through the range in an effort to standardise the procedure. Assessment and 
measurements were conducted as outlined in Appendix 10.  
6. Isometric muscle strength of bilateral upper and lower limb muscles was tested 
using the MicroFET2 Dynamometer (Hoggan Health Industries Inc, Draper, Utah). It 
measured strength in pounds and this was then converted to Newtons. For all 
testing, the ‘L’ or lower threshold setting was used as it is more sensitive. A ‘make 
test’ was performed, in which the HHD was stabilised by the investigator, while the 
participants were asked to “Push as hard as you can” for 5 seconds against the 
HHD. All movements were demonstrated to the patients and one or two practice 
trials were performed to familiarise the participants to the procedure. Two trials were 
measured for each muscle group. The following muscle groups were assessed 
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supine: shoulder flexion and abduction, elbow flexion and extension, hip abduction 
and ankle plantarflexion. Hip flexion, knee flexion and knee extension were 
assessed in sitting. The average score over two trials was calculated and rounded 
off to one decimal place for each muscle group. The testing protocol as used by 
Willemse et al (2013) was followed (see Appendix 11). 
 
3.7 Statistical analyses 
The null hypothesis stated that there is no difference between the two groups’ clinical 
presentation in terms of function, tone and strength.  
 
All data collected was analysed in consultation with a statistician using STATA 12 software 
(Stata Corp, Texas, USA) and STATISTICA Version 12.7.   
Significance was set at p<0.05 however, for crude analysis, the significance level was also 
set as p<0.1 as the sample size was small. Furthermore, GMFCS classification was 
condensed into two groups based on the ability of the participants to walk. Therefore, 
participants of GMFCS level I and II were grouped together and were named the functional 
group while participants in levels III and IV represent the non-functional group. 
3.7.1 Descriptive and inferential statistics 
Descriptive statistics were used to summarise collections of data. The demographic 
information of the HIV infected and uninfected groups were analysed using means, 
standard deviations, percentages, minimum and maximum values.  
The WHO AnthroPlus software for personal computers versions 3.2.2 was used to convert 
the weight and height measurements into z-scores for all participants. These scores were 
analysed using student t-tests. 
 
Inferential statistics were used to determine the statistical significance of relationships 
between the variables, and to statistically contrast these relationships.  Normality for 
continuous variables was assessed using Shapiro-Wilk tests. Data which was not normally 
distributed was transformed to fit a normal distribution. Student t-tests were performed on 
normally distributed or transformed data. This test is used where there are two different 
experimental conditions (the HIV infected and uninfected group as well as the functional 
and non –functional group). These tests were applied to analysis of GMFM and muscle 
strength values.  
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The modified Ashworth scale and FMS represented ordinal data. In order to determine the 
statistical significance of the relationship of these variables between the two groups, non-
parametric Mann-Whitney U tests were used. 
3.7.2 Correlation statistics 
The Pearson Product Moment-Correlation Coefficient (r) is a correlation between two 
variables. It is used to determine the degree of relationship between variables.  Two-tailed 
t-tests were employed in order to determine whether or not these relationships are 
statistically significant.   
Pearson correlation analyses were done in order to determine the relationship between 
viral load and GMFM, strength, weight and height in the HIV infected group as well as 
between GMFM and age.   
 
3.8 Conclusion 
The results obtained will be presented in the following chapter. 
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CHAPTER 4 - RESEARCH RESULTS 
 
4.1 Introduction 
This chapter will present the results of the study. Interpretation and discussion of the 
results will follow in chapter five. 
 
4.2 Descriptive and inferential statistics 
4.2.1. Gender demographic 
Figure 4.1 depicts the gender composition of the each group.  There was a predominance 
of males (80.6%) in the HIV uninfected group while there was a more even gender 
distribution in the HIV infected group (boys=51.5%; girls=48.5 %). 
 
 
 
 
Figure 4.1 Gender Demographic of HIV infected and uninfected groups 
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4.2.2 Age Demographic 
Table 4.1 indicates the age of children in the HIV infected and HIV uninfected groups while 
Table 4.2 summarises the distribution of the functional (GMFCS I and II) and non-
functional (GMFCS III and IV) groups.  
 
Table 4.1: Age demographic information for HIV infected and uninfected groups 
 
HIV infected 
n=33 
HIV Uninfected 
n=31 
 
 
Mean 
(SD) 
Minimum Maximum 
Mean 
(SD) 
Minimum Maximum 
Probability 
Value (p) 
Age (years) 
7.78 
(2.57) 
4.0 15.0 
8.77 
(3.26) 
4.0 16.0 0.18 
 
The two groups were well matched for age. 
 
 
Table 4.2: Age demographic information for HIV infected and uninfected, functional and 
non-functional groups 
 
Non functional group 
(n=36) 
Functional Group 
(n=28) 
Analysis 
 
HIV 
Infected 
(n=16) 
 
HIV 
Uninfected 
(n=20) 
 
p Value 
HIV 
Infected 
(n=17) 
 
HIV 
Uninfected 
(n=11) 
 
p Value 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Age 
(years) 
8.06 
(2.35) 
7.8 
(3.04) 
0.78 
7.53 
(2.76) 
10.55  
(3.01) 
0.01** t-test 
* Comparison was significant at the 0.1 level  
** Comparison was significant at the 0.05 level  
 
When comparing the age of participants in the HIV infected to uninfected group, there is 
no statistical significance (p=0.18) between the groups. The groups appear evenly 
matched. 
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However, there is a statistical significance (p=0.01) in the functional group. The HIV 
infected functional participants were significantly younger than their uninfected 
counterparts.  
4.2.3 GMFCS distribution  
The GMFCS distribution across the HIV infected and uninfected groups is presented in 
Figure 4.2. 
 
 
Figure 4.2: GMFCS distribution for HIV infected and uninfected groups 
There was an uneven distribution across the four levels. With a Pearsons Chi² analyses, 
the p value was 0.542, indicating that there was no significant difference between the 
groups.  
 For the purposes of crude analyses GMFCS I and II were grouped together (functional 
group), while levels III and IV were grouped as the non-functional group. Table 4.3 shows 
the revised distribution of the condensed groups. 
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Table 4.3 GMFCS distribution for HIV infected and uninfected functional and non-functional 
groups 
 
 
HIV 
Infected 
HIV 
Uninfected 
   n n 
Functional GMFCS I + II 17 11 
Non-
Functional GMFCS III + IV 16 20 
 
 The functional group was able to walk either independently or with assistance while the 
non-functional group was predominantly wheelchair bound. This means that participants in 
the GMFCS III category were household ambulators only and used a wheelchair for longer 
distances. Those in the GMFCS IV category were able to crawl around the house but 
needed a wheelchair for longer distances. Pearsons Chi² test showed no significant 
difference between the groups (p= 0.196). There is a trend for the HIV uninfected group to 
be less functional.  
4.2.4 Demographic information 
Additional demographic information for both groups is presented in Table 4.4.  Relevant 
information from the medical questionnaire that was completed by the parent or caregiver 
was extracted. 
   
Table 4.4 Demographic information for HIV infected and uninfected groups 
 
Total n=64 
 HIV Infected HIV Uninfected 
  n Percentage n Percentage 
Total per group 33   31   
Botox 19 57.6 18 58.1 
Surgery 1 3.0 4 12.9 
Medication 
HAART 32 97.0 0 0 
Ritalin 2 6.0 6 19.4 
Epilim 0 0 3 9.7 
Risperdal  0 0 2 6.5 
Baclofen  0 0 1 3.0 
Birth Complications  
Prematurity 3 9.1 13 41.9 
Long labour /anoxia 4 12.1 5 16.1 
one of twin 1 3.0 3 9.7 
unknown-orphan 5 15.2 0 0 
unknown history 4 12.1 0 0 
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Illness < 1 year 
None 13 39.4 21 67.7 
Respiratory 13 39.4 2 6.5 
Meningitis 1 3.0 1 3.2 
VP shunt 0 0 3 9.7 
Fits 2 6.1 2 6.5 
Other 0 0 2 6.5 
Unknown 4 12.1 0 0 
Milestones 
Delayed 33 100 31 100 
Loss of milestones 3 9.1 0  0 
School History 
Pre school 5 15.2 2 6.5 
***LSEN- mainstream 13 39.4 13 42.0 
***LSEN special 8 24.2 9 29.0 
Mainstream 4 12.1 1 3.2 
Stimulation 2 6.1 5 16.1 
not in school 1 3.0 1 3.2 
repeated grades 3 9.1 8 25.8 
  ***LSEN- refers to schools for learners with special educational needs 
 
Botox was done almost equally across the groups (57.6% and 58.1%). The frequency of 
prematurity as well as other complications like pre-eclampsia was higher in the HIV 
uninfected group. Unknown birth history as a result of parents being deceased was only 
prevalent in the HIV infected group. Illness requiring re-admission into hospital was 
prevalent in both groups. The most common cause of illness under a year was respiratory 
complications (39.4 %) in the HIV infected group. All participants had delayed milestones 
but three participants in the HIV infected group had attained all motor milestones and then 
lost them at a later age. Ninety seven percent of participants in both groups attended 
school. The majority of participants in both groups attended a school for learners with 
special educational needs (LSEN) (63.6% and 71%).  
4.2.5 HIV infected group demographics 
Table 4.5 provides additional insight into the demographics of the HIV infected group with 
regard to medication and viral load. Only one participant in this group was not receiving 
HAART while one participant had defaulted on his medication.  
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Table 4.5: Viral load and initiation of HAART in HIV infected group 
HIV Infected group- Viral Load 
 
N Percentage 
Total number of 
participants 32 97 
LTD- <20 
copies/ml 12 37.5 
20-400 14 43.8 
400-1000  2 6.3 
>1000 4 12.5 
Age of HAART initiation 
birth-6 weeks 5 15.6 
6wks - 6 months 10 31.3 
6 -12 months 10 31.3 
1-2 years 3 9.4 
>2 years 3 9.4 
Unknown 1 3.0 
    
Thirty two participants were receiving HAART at the time of the assessment. Viral load 
values ranged from lower than detectable (LTD) to 21658copies/ml. 
HAART initiation was most frequent between 6 weeks and 1year (62.6%). Early HAART 
initiation from birth to 6 weeks was only observed in 15.6% of participants. One participant 
was being cared for in a home therefore the age of HAART initiation was unknown. 
 
4.2.6 Anthropometric data 
4.2.6.1 Anthropometric data to compare HIV infected and uninfected groups to the norm for 
their age 
Tables 4.6 and 4.7 show the comparison of the participant’s height-for-age, weight-for-age 
and BMI-for-age z scores.  A two sample student’s t test of equal variance was used to 
compare the groups. There were no height and weight measurements taken for one 
participant in the HIV infected group therefore 32. 
Depending on the age, z scores were calculated using either the WHO standards (0-
5years) or the WHO reference (5-19years). For children over the age of 10, weight-for-age 
is no longer regarded as a good indicator of growth as many children are experiencing 
puberty. They may appear to have excess weight but in fact they may be just tall. Seven 
participants were over the age of ten in the non-functional group and similarly there were 
eleven participants over the age of 10 in the functional group. Therefore, there were no 
weight-for-age scores for these participants. 
Means, standard deviations, minimum and maximum values are included.   
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Table 4.6:  Comparison of z scores for HIV infected and uninfected groups 
 
HIV Infected 
32 
HIV Uninfected 
31 
 
 
Mean 
(SD) 
Minimum Maximum 
Mean 
(SD) 
Minimum Maximum 
Probability 
Value (p) 
Height-
for- age z 
score 
-1.61 
(2.02) 
-5.07 2.84 
-1.75 
(1.81) 
-5.73 1.59 0.78 
Weight-
for-age z 
score 
24 
-0.67 
(1.62) 
 
-3.79 3.31 
21 
-0.66 
(1.62) 
-3.66 2.48 1.0 
BMI-for-
age z 
score 
0.51 
1(1.47) 
-2.4 0.88 
0.03 
(1.70) 
-3.66 2.86 0.24 
 
There were no significant differences in z scores between the two groups. The weight-for-
age and BMI-for-age mean z scores for the HIV infected and HIV uninfected groups lies 
between negative one and positive one. This indicates that both groups fall within the 
median percentile for these growth parameters. Mean height-for-age for both groups lies 
between negative two and negative one. This indicates that they fall in the fifteenth 
percentile for height, indicating that participants in both groups are shorter than the median 
for the age group.  
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Table 4.7:  Comparison of z scores for HIV infected and uninfected, functional and non-
functional groups 
 
Non functional group 
(36) 
Functional Group 
(28) 
 
HIV 
Infected 
(16) 
 
HIV 
Uninfected 
(20) 
 
p Value 
HIV 
Infected 
(16) 
 
HIV 
Uninfected 
(11) 
 
p Value 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Height-
for- age z 
score 
-2.38 
(2.07) 
-1.81   
(2.10) 
0.40 
-0.84 
(1.89) 
-1.63  
(1.20) 
0.23 
Weight-
for-age z 
score 
n=13 
-0.91 
(2.16) 
n=16 
-0.48   
(1.81) 
0.56 
n=11 
-0.39 
(1.06) 
n=5 
-1.26  
(0.53) 
0.11 
BMI-for-
age z 
score 
0.76  
(1.49) 
0.15 
(1.81) 
0.29 
0.26  
(1.45) 
-0.18  
(1.55) 
0.46 
* Comparison was significant at the 0.1 level  
** Comparison was significant at the 0.05 level  
 
In the non- functional group, the mean height-for-age of the HIV infected group and HIV 
uninfected group fell into the 3rd percentile and the 15th percentile respectively.  Weight 
and BMI-for-age for both groups fell into the 50th percentile. The trend in this group was for 
the HIV infected participants to be shorter and lighter.  
In the functional group the mean z scores fell into the following percentiles:  Height-for-age 
(HIV infected) - 50th percentile, height-for-age (HIV uninfected) - 15th percentile, weight -
for-age (HIV infected) - 50th percentile, weight-for-age (HIV uninfected) - 15th percentile, 
BMI-for-age HIV infected and HIV uninfected - 50th percentile. The HIV infected 
participants had a tendency to be taller and heavier in this group. 
No significant differences were noted in the z scores for weight-for-age, height-for-age or 
BMI-for age between the HIV infected and HIV uninfected groups. A significant difference 
(p=0.02) exists between the heights of the functional and non functional HIV infected 
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group indicating that participants in the non-functional group are significantly shorter than 
the functional participants. 
4.2.6.2 Correlation between viral load and weight and height 
The correlation between viral load, weight and height was determined using Pearson’s 
Product Moment-Correlation Coefficient (r) and probability value (p) was calculated using 
student t-tests to determine if this correlation was true. 
There was a moderate correlation between viral load and weight (r=0.38, p=0.03) and 
height (r=0.36, p=0.04) which was significant. 
4.2.7 GMFM 
Table 4.8 and 4.9 summarise the means, standard deviations and p values of the GMFM 
scores for the HIV infected, uninfected, functional and non-functional groups. 
Table 4.8 GMFM scores for HIV infected and uninfected groups 
 
HIV Infected 
33 
HIV Uninfected 
31 
 
 
Mean 
(SD) 
Minimum Maximum 
Mean 
(SD) 
Minimum Maximum 
Probability 
Value (p) 
GMFM Total 
62.59 
(11.07) 
44.6 85.2 
58.72 
(9.89) 
46.3 84 0.15 
% Dimension 
A 
100.00 
(0) 
100.00 
 
100.00 
 
100.00 
(0) 
100.00 
 
100.00 
 
1.0 
% Dimension 
B 
98.59 
(4.90) 
73.3 100 
97.50 
(5.98) 
80 100 0.43 
% Dimension 
C 
95.76 
(7.14) 
70 100 
95.70 
(5.85) 
76.7 100 0.98 
% Dimension 
D 
59.35 
(28.47) 
7.7 97.4 
48.97 
(28.33) 
4.2 92.3 0.15 
% Dimension 
E 
48.81 
(32.53) 
5.5 95.8 
37.40 
(28.77) 
2.8 97.3 0.13 
* Comparison was significant at the 0.1 level  
** Comparison was significant at the 0.05 level  
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Table 4.9 GMFM scores for HIV infected and uninfected, functional and non-functional 
groups 
 
Non functional group 
(36) 
Functional Group 
(28) 
 
HIV 
Infected 
(16) 
 
HIV 
Uninfected 
(20) 
 
p Value 
HIV 
Infected 
(17) 
 
HIV 
Uninfected 
(11) 
 
p Value 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
GMFM Total 
53.13 
(5.39) 
 
53.78 
(4.76) 
 
0.74 72.22 
(6.63) 
 
69.86 
(6.20) 
 
0.52 
% Dimension 
A 
100 
(0) 
 
100 
(0) 
 
1.0 100 
(0) 
 
100 
(0) 
 
1.0 
% Dimension 
B 
97.09 
(6.83) 
 
96.13 
(7.13) 
 
0.82 100 
(0) 
 
100 
(0) 
 
1.0 
% Dimension 
C 
92.91 
(9.35) 
 
93.84 
(6.43) 
 
0.90 98.44 
(2.08) 
 
99.09 
(2.16) 
 
0.27 
% Dimension 
D 
36.86 
(22.70) 
 
32.20 
(19.80) 
 
0.60 80.52 
(12.49) 
 
79.48 
(8.74) 
 
0.54 
% Dimension 
E 
19.52 
(14.77) 
 
18.95 
(14.11) 
 
0.73 76.38 
(15.71) 
 
70.08 
(15.78) 
 
0.16 
 * Comparison was significant at the 0.1 level  
** Comparison was significant at the 0.05 level  
 
There were no significant differences between groups with regard to GMFM scores.  There 
is a trend for the HIV infected participants to perform better in the functional group and this 
is most noticeable in Dimension E (walking, running and jumping) where there is a 
difference in scores of 6.3%. 
4.2.7.1 Correlation between GMFM and viral load 
No significant correlation was found between viral load and GMFM in the HIV infected 
group (r=0.18, p=0.3). Correlation statistics were performed using Pearson’s Product 
Moment-Correlation Coefficient (r). 
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4.2.7.2 Correlation between GMFM and age 
No significant correlation was found between age and GMFM in the HIV infected group 
(r=0.18, p=0.12). However, a moderate correlation which was found to be significant 
(r=0.66, p=0.03) was found between age and GMFM of the HIV uninfected, functional 
participants. Correlation statistics were performed using Pearson’s Product Moment-
Correlation Coefficient (r) and student t-tests were used to determine if it was significant. 
The results of this analysis can be found in Appendix 16. 
4.2.7.3 Comparison of GMFM scores to percentiles of each GMFCS level 
Hanna et al (2008) created reference percentiles for each GMFCS level according to their 
age group. This was used as a reference to determine the percentiles for each HIV 
infected and uninfected group at each GMFCS level. These results are shown in Table 
4.10.  
Table 4.10 Percentiles of each GMFCS level using mean age and mean GMFM score   
 GMFCS I GMFCS II GMFCS III GMFCS IV 
 HIV 
Infected 
HIV 
Uninfected 
HIV 
Infected 
HIV 
Uninfected 
HIV 
Infected 
HIV 
Uninfected 
HIV 
Infected 
HIV 
Uninfected 
A
g
e
 
(y
e
a
rs
) 7.7 12.2 7.3 9.2 8.3 7.5 7.7 8.3 
M
e
a
n
 
G
M
F
M
  
 
75.1 74.3 66.3 66.2 55.8 55.1 48.6 47.9 
P
e
rc
e
n
ti
le
 
15-20 10-15 55 40 60-65 60-65 80-85 80-85 
 
The GMFM score for the HIV infected and uninfected participants in the non-functional 
group fell within the same percentiles while those of the HIV infected participants in the 
functional fell within a higher percentile compared to the HIV uninfected participants. 
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4.2.8 Functional Mobility Scale 
FMS scores for the groups were compared using Mann-Whitney U tests as the data is 
ordinal.  
There were no significant differences between the HIV infected and HIV uninfected groups 
as a whole, at 5meters (p=0.18), 50meters (p=0.14) and 500meters (p=0.08). At five 
hundred meters there is a significance if p<0.1. 
Figures 4.3 and 4.4 represent the frequency in the form of percentages for each level in 
the three categories of the FMS for the functional and non-functional groups.  
The FMS evaluates the mobility of children with CP at different distances. Each level of the 
scale indicates how a participant mobilises at that distance. N represents not applicable; C 
represents crawling; 1represents use of a wheelchair; 2 indicates that a participant walks 
with a walking frame; 3 indicates that a participant walks with crutches; 4 indicated that 
they walk with one or two sticks; 5 indicates that a participant can walk independently over 
even surfaces while 6 means that they can walk independently over all surfaces. These 
levels are represented in the figures below. 
 
 
Figure 4.3 FMS frequency for non-functional HIV infected and uninfected groups  
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There were no significant differences between the non-functional HIV infected and HIV 
uninfected groups at 5meters (p=0.87), 50meters (p=0.94) and 500meters (p=0.54). The 
majority of participants in both groups crawl at 5meters and use wheelchairs at 50 and 500 
meters. 
 
Figure 4.4 FMS frequency for functional HIV infected and uninfected groups  
 
There was no significant difference between the HIV infected and HIV uninfected 
participants in the functional group at 5meters (p=0.61), 50meters (p=0.29) and 500meters 
(p=0.30). The majority of the participants were able to walk independently at 5, 50 and 500 
meters. There was an increase in the use of an assistive device like a crutch or stick as 
the distance increased.  
 
4.2.9 Muscle Tone 
The scores attained using the MAS were compared using Mann-Whitney U analyses as 
the data is ordinal. The scale represents different degrees of spasticity that is felt in a 
muscle group. Table 3.1(pg 47) gives a description of each level of spasticity in this scale.  
There is no significant difference in tone when comparing HIV infected to uninfected 
participants. Similarly there were no significant differences between the HIV infected and 
HIV uninfected participants in the functional group. Significantly lower right (p=0.03) and 
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left (p=0.1) adductor tone was found in the HIV infected children who are graded non 
functional. P values for the comparison of these groups are documented in Table 4.11. 
 
Table 4.11 P values of comparative MAS scores of HIV infected and uninfected, functional 
and non-functional groups 
 
Non-functional 
Group 
Functional 
Group 
 p Value p Value 
Adductor Left  0.10* 0.98 
Adductor Right 0.03** 0.59 
Hamstring Left 0.93 0.23 
Hamstring Right 1.00 0.90 
Gastrocnemius 
Left 
0.97 0.73 
Gastrocnemius 
Right 
0.95 0.22 
Soleus Left 0.38 0.49 
Soleus Right 0.86 0.60 
* Comparison was significant at the 0.1 level  
** Comparison was significant at the 0.05 level  
 
In order to determine the pattern of spasticity in the functional and non-functional groups, 
the average percentage of the frequency in each muscle group was calculated across both 
the left and right side. Furthermore, grade one and one plus was grouped together as mild 
tone, grade two as moderate tone while grade three and four was grouped together as 
severe tone. 
Table 4.12 and Table 4.13 below summarise these percentages for the functional and non-
functional group. 
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Table 4.12 Average frequencies expressed as percentages for tone across two sides in 
functional group 
 Tone Adductors Hamstrings Gastrocnemius Soleus 
HIV infected 
(17) 
 
No Increased 
tone (0) 
8.9% 0% 5.9% 5.9% 
Mild (1/ 1+) 64.7% 55.9% 55.9% 58.8% 
Moderate (2) 26.5% 41.2% 32.4% 38.3% 
Severe (3/4) 0% 5.9% 8.9% 0% 
HIV 
uninfected 
(11) 
No Increased 
tone (0) 
9.1% 0% 9.1% 18.1% 
Mild (1/ 1+) 50% 36.4% 63.7% 72.8% 
Moderate (2) 27.3% 36.4% 31.9% 18.2% 
Severe (3/4) 9.1% 27.2% 0% 0% 
 
The frequency of mild tone accounted for more than 50% of the tone across all muscle 
groups in the HIV infected participants. The incidence of severe tone was less than 10% 
and only prevalent in the hamstrings (5.9%) and gastrocnemius (8.9%) muscle groups.  
In the HIV uninfected participants, mild tone increased in frequency from proximal to distal 
while severe tone decreased from proximal to distal. However, almost one third of the 
group (27.2%) had severe tone in the hamstrings. Overall, both the HIV infected and 
uninfected groups presented predominantly with mild tone.  
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Table 4.13 Average frequencies expressed as percentages for tone across two sides in non-
functional group 
 Spasticity Adductors Hamstrings Gastrocnemius Soleus 
HIV infected 
(16) 
No Increased 
tone (0) 
6.3% 0% 0% 0% 
Mild (1/ 1+) 28.2% 34.5% 65.7% 53.2% 
Moderate (2) 40.5% 37.5% 21.9% 37.6% 
Severe (3/4) 15.7% 28.2% 12.5% 9.4% 
HIV 
uninfected 
(20) 
No Increased 
tone (0) 
0% 0% 5% 5% 
Mild (1/ 1+) 30% 20% 55% 72.5% 
Moderate (2) 20% 37.5% 35% 27.5% 
Severe (3/4) 55% 42.5% 12.5% 12.5% 
 
In the non-functional group, the HIV infected participants had a predominance of mild tone 
distally and moderate tone proximally. The greatest frequency of severe tone was 
observed in the hamstrings (28.2%). The frequency of mild tone increased from proximal 
to distal.  
The non functional HIV uninfected participants had a greater frequency of severe tone 
proximally in the hip adductors (55%) and hamstrings (42.5%) while the frequency of mild 
tone was more prevalent in the distal muscle groups. It can be said that the severity of 
tone decreased from proximal to distal in this group.  
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4.2.10 Muscle strength 
Muscle strength data (mean, standard deviation, minimum and maximum values) for both 
groups are given in Table 4.14 and 4.15. A two sample student’s t test of equal variance 
was used to compare groups. Values of muscle strength are represented in Newtons (N). 
 
Table 4.14 Muscle strength scores for HIV infected and uninfected groups 
 
HIV Infected 
33 
HIV Uninfected 
31 
 
Muscle 
Group 
Mean 
(SD) 
Minimum Maximum 
Mean 
(SD) 
Minimum Maximum 
Probability 
Value (p) 
Shoulder 
Abduction 
Left 
23.04 
(8.79) 
11.57 46.71 
22.31 
(10.24) 
7.12 54.27 0.76 
Shoulder 
Abduction 
Right 
21.86 
(9.21) 
7.56 49.38 
21.60 
(10.11) 
5.78 50.71 0.91 
Shoulder 
Forward 
Flexion Left 
22.96 
(9.12) 
10.68 43.59 
23.93 
(12.55) 
9.79 59.61 0.61 
Shoulder 
Forward 
Flexion 
Right 
23.28 
(8.97) 
10.23 43.59 
23.69 
(12.80) 
8.01 58.27 0.88 
Elbow 
Flexion Left 
25.62 
(10.84) 
8.90 44.93 
26.62 
(14.82) 
8.90 67.61 0.76 
Elbow 
Flexion 
Right 
26.04 
(11.18) 
6.67 51.15 
25.25 
(15.29) 
9.34 77.84 0.81 
Elbow 
Extension 
Left 
25.54 
(9.87) 
9.34 44.04 
25.48 
(14.47) 
7.12 72.06 0.98 
Elbow 
Extension 
Right 
26.77 
(12.60) 
4.89 61.83 
24.61 
(13.75) 
8.90 63.16 0.51 
Hip 
Abduction 
Left 
19.49 
(8.90) 
7.12 44.93 
21.55 
(12.67) 
6.23 71.17 0.45 
Hip 
Abduction 
Right 
21.62 
(9.88) 
5.34 52.49 
21.91 
(11.02) 
7.12 61.39 0.91 
Ankle 
Plantarflex 
Left 
15.77 
(7.65) 
4.45 45.82 
14.44 
(5.56) 
8.01 32.47 0.43 
Ankle 
Plantarflex 
Right 
15.56 
(6.61) 
5.34 33.36 
12.81 
(4.23) 
5.78 28.47 0.05** 
Knee 
Flexion Left 
18.06 
(6.98) 
7.12 33.81 
19.29 
(13.14) 
4.45 68.06 0.64 
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Knee 
Flexion 
Right 
19.33 
(7.70) 
8.45 41.81 
19.86 
(12.14) 
6.23 53.38 0.83 
Knee 
Extension 
Left 
19.80 
(10.63) 
7.12 52.93 
20.42 
(11.28) 
6.23 53.82 0.82 
Knee 
Extension 
Right 
19.09 
(9.26) 
5.34 44.93 
21.54 
(11.37) 
5.78 44.93 0.33 
Hip Flexion 
Left 
19.80 
(9.08) 
6.67 37.81 
20.72 
(11.31) 
8.01 58.27 0.72 
Hip Flexion 
Right 
19.18 
(8.91) 
8.45 45.82 
20.59 
(11.13) 
6.23 52.93 0.58 
* Comparison was significant at the 0.1 level (2-tailed) 
** Comparison was significant at the 0.05 level (2-tailed) 
 
For the most part there is no significant difference between the groups except, that the HIV 
infected participants have significantly stronger ankle plantarflexors (p=0.05) on the right. 
 
There were no consistent significant differences between the functional and non- 
functional groups. HIV infected functional participants were significantly stronger in right 
ankle plantarflexors (p=0.10), but weaker in right knee flexion (p= 0.08) and extension 
(p=0.10). HIV infected non-functional participants were significantly stronger in right elbow 
extension (p=0.05) and right knee flexion (p=0.09).   
Although there were no significant statistical findings the following trends were observed. 
In the functional group, the HIV uninfected participants tended to be stronger in all muscle 
groups except right and left ankle plantar flexion.  In the non-functional groups there was a 
tendency for the HIV infected participants to be stronger in all muscle groups except right 
knee extension and left hip abduction.  
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Table 4.15 Muscle strength scores for HIV infected and uninfected, functional and non-
functional groups 
 
Non functional group 
(36) 
Functional Group 
(28) 
 
HIV 
Infected 
(16) 
 
HIV 
Uninfected 
(20) 
 
p Value 
HIV 
Infected 
(17) 
 
HIV 
Uninfected 
(11) 
 
p Value 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Shoulder 
Abduction 
Left 
22.55 
(7.81) 
19.44 
(10.59) 
0.14 
23.51 
(9.84) 
27.54 
(7.43) 
0.16 
Shoulder 
Abduction 
Right 
20.88 
(9.13) 
17.97 
(7.46) 
0.36 
22.79 
(9.47) 
28.19 
(11.25) 
0.16 
Shoulder 
Flexion Left 
22.35 
(8.07) 
22.04 
(12.30) 
0.93 
23.52 
(10.22) 
27.38 
(12.84) 
0.38 
Shoulder 
Flexion Right 
21.05 
(7.56) 
19.44 
(9.42) 
0.58 
25.38 
(9.88) 
31.42 
(14.88) 
0.21 
Elbow 
Flexion      
Left 
26.08 
(11.29) 
21.66 
(9.34) 
0.25 
25.20 
(10.73) 
35.63 
(18.83) 
0.20 
Elbow 
Flexion     
Right 
25.72 
(11.52) 
20.35 
(8.50) 
0.18 
26.35 
(11.19) 
34.17 
(20.71) 
0.41 
Elbow Ext  
Left 
24.83 
(10.44) 
21.11 
(11.04) 
0.31 
26.22 
(9.57) 
33.44 
(16.98) 
0.16 
Elbow Ext  
Right 
26.24 
(11.59) 
19.46 
(8.29) 
0.05** 
27.26 
(13.82) 
33.97 
(16.95) 
0.26 
Hip 
Abduction 
Left 
18.24 
(9.14) 
18.99 
(9.40) 
0.85 
20.67 
(8.78) 
26.20 
(16.64) 
0.30 
Hip 
Abduction 
Right 
18.90 
(9.19) 
17.79 
(7.16) 
0.96 
24.18 
(10.09) 
29.40 
(13.10) 
0.22 
Ankle 
Plantarflex 
Left 
14.26 
(5.07) 
13.47 
(3.73) 
0.88 
17.19 
(9.41) 
16.22 
(7.80) 
0.86 
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Ankle 
Plantarflex 
Right 
13.79 
(5.74) 
12.66 
(3.25) 
0.76 
17.22 
(7.10) 
13.10 
(5.78) 
0.10* 
Knee Flexion 
Left 
17.54 
(6.63) 
15.26 
(7.86) 
0.21 
18.55 
(7.47) 
26.61 
(17.58) 
0.22 
Knee Flexion 
Right 
20.68 
(8.78) 
16.41 
(10.45) 
0.09* 
18.05 
(6.53) 
26.12 
(12.95) 
0.08* 
Knee 
Extension 
Left 
17.65 
(11.71) 
16.24 
(6.93) 
0.95 
21.82 
(9.42) 
28.02 
(13.85) 
0.22 
Knee 
Extension 
Right 
16.82 
(9.51) 
17.77 
(8.24) 
0.64 
21.22 
(8.77) 
28.39 
(11.75) 
0.10* 
Hip Flexion 
Left 
16.60 
(8.91) 
16.24 
(5.82) 
0.72 
22.82 
(8.40) 
28.87 
(14.34) 
0.26 
Hip Flexion 
Right 
17.18 
(8.82) 
16.12 
(5.88) 
0.89 
21.06 
(8.84) 
28.71 
(13.92) 
0.15 
* Comparison was significant at the 0.1 level (2-tailed) 
** Comparison was significant at the 0.05 level (2-tailed) 
 
4.2.10.1 Correlation between viral load and muscle strength 
Pearson’s Product Moment-Correlation Coefficient was used to determine if a relationship 
existed between viral load and muscle strength in the HIV infected participants. A 
moderate correlation (r= 0.35-0.48) which is significant (p<0.05) was found in six muscle 
groups suggesting that viral load may have an impact on muscle strength in children with 
HIV. The data of this analysis can be found in Appendix 16. 
 
Since there is no consistency in difference in muscle strength between the groups, 
regression analysis was not done. 
 
4.6 Summary of results 
4.6.1 Results of comparison of HIV infected and HIV uninfected groups 
Participants were well matched for age, GMFCS level, weight and height. 
The only significant differences between these groups, was for FMS at 500 meters and 
right ankle plantarflexor strength. The HIV uninfected group performed better in the FMS at 
500 meters and had significantly weaker right ankle plantarflexor strength. 
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When comparing participants in the HIV infected group, the functional participants were 
significantly taller than the non functional participants. There was a moderate correlation 
between viral load and weight and height and viral load and six muscle groups for the HIV 
infected participants. 
 
4.6.2 Results of comparison of HIV infected and HIV uninfected, functional groups 
There were no statistically significant differences for GMFCS, weight, GMFM scores, FMS 
and majority of muscles tested for tone and strength. There was no significant correlation 
between viral load and GMFM. 
The following were found to be statistically significant: 
 Functional  HIV infected children were younger than HIV uninfected children 
 Functional HIV infected children had stronger right ankle plantarflexors but 
weaker right knee flexors and extensors than functional HIV uninfected 
children 
 A moderate significant correlation was found between age and GMFM scores 
of the HIV uninfected participants 
The following trends were observed: 
 The HIV infected participants scored better in the GMFM, particularly in Dimension 
E where there was a 6.3% difference in scores. 
 The HIV infected participants had a predominance of mild tone from proximal to 
distal. 
 Severe hamstring tone was prevalent in almost one third of the HIV uninfected 
participants compared to less than 10% in the HIV infected participants. 
 The HIV infected participants were weaker in all muscle groups except that of ankle 
plantarflexors compared to the HIV uninfected participants 
 
4.6.3 Results of comparison of HIV infected and uninfected, non functional groups 
There were no statistically significant differences for GMFCS, weight, GMFM scores, FMS 
and majority of muscles tested for tone and strength. There was no significant correlation 
between viral load and GMFM. 
The following were found to be statistically significant: 
 Non-functional  HIV infected children had less right and left adductor tone 
compared to HIV uninfected children 
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 Non-functional HIV infected children had stronger right elbow extensors and 
right knee flexors than  HIV uninfected children 
The following trends were observed: 
  The HIV infected and HIV uninfected groups had similar GMFM scores in all 
dimensions 
 The HIV infected participants had a greater frequency of mild tone compared 
to the HIV uninfected participants. 
 The HIV uninfected participants presented with severe tone proximally in 
50% of cases while the HIV infected group presented with more moderate 
tone proximally 
 The HIV infected participants were stronger than the HIV uninfected 
participants in all muscle groups. 
 
4.7 Conclusion 
The research results presented in this chapter facilitate both a description of the data 
collected and presentation of the inferential statistics needed to examine the research 
aims and objectives. Interpretation and discussion of these results will follow in chapter 
five. 
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CHAPTER 5 - DISCUSSION 
 
5.1 Introduction 
The primary aim of this study was to determine if there are similarities and differences 
between children with diplegia as a result of CP and HIVE. This chapter serves to interpret 
and discuss the results of the present study. Clinical implications, limitations of the study 
and implications for future research will be discussed.  
 
Children of school going age were chosen because HIV infected infants are surviving into 
adolescence and adulthood but they are living with the complications of HIVE such as 
diplegia. They are accessing the South African school system and management and 
rehabilitation of these children is becoming increasingly relevant.  
 
5.2 Demographic data 
5.2.1 General 
Children from both groups were divided into a functional group (GMFCS I and II), who 
were independently ambulant and a non-functional group (GMFCS III and IV) who were 
more limited in self mobility. This was done to be able to compare similar groups of 
children based on function. The rationale for the stratification is based studies by Palisano 
et al (2000) and Oeffinger et al (2009). Palisano et al (2000) found that the difference 
between the GMFM scores between GMFCS level II and III can differ by up to twenty-eight 
points and in contrast the difference between GMFCS level I and II was only 7.5 points 
while Oeffinger found that there is a large overlap between GMFCS I and II but no overlap 
between II and III. This indicates that the attainable gross motor function varies very little 
between level I and II and that children in level II may take longer to attain their maximum 
function (Palisano et al, 2000). 
In splitting the groups, the sample size of each of the four groups was much smaller which 
could explain the lack of statistical significance in GMFCS distribution. 
Children were well matched for age and gender between the HIV infected and HIV 
uninfected groups. 
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There was a higher incidence of prematurity in children with CP (41.9%) compared to 
those with HIV (9.1%). Prematurity is one of the most common known causes of CP 
(Odding et al, 2006) however in an African setting it was only identified by two studies as a 
major cause (Donald et al, 2014a). The use of HAART by the mother prior to pregnancy or 
in the first trimester may predisposes her to premature delivery (Mirpuri and Jain, 2010) 
which could account for the three children with HIV that were born prematurely. In 
resource-rich settings elective caesarean sections are offered to women to reduce the risk 
of mother-to-child transmission (Mirpuri and Jain, 2010), but is not common practice in the 
public health setting in South Africa. 
In Africa, anoxia was noted as the most common risk factor for CP (Donald et al, 2014a). 
The incidence of anoxia was similar between the groups. However for the CP group, 
prematurity was still a more prevalent cause than anoxia. 
Five children in the HIV infected group were orphans compared to none in the HIV 
uninfected group. One was in an institution and four were being cared for by family 
members. Children with HIV are at greater risk of orphanhood as parents are also affected 
by the epidemic. They may also have to bear the burden of siblings and other family 
members being affected. Extended families and institutions provide care for these children 
(Jelsma et al, 2011; Shead et al, 2010) but will have to cope with the extra burden of 
disability. 
The definitions of both CP and HIVE, state that motor milestones may be delayed 
(Rosenbaum et al, 2007; WHO, 2007). As per these definitions, motor milestones were 
delayed in all participants in this study. Furthermore the definition of HIVE also 
acknowledges the loss of a previously acquired skill (WHO, 2007). This was true for three 
participants with HIVE whose milestones regressed.  
In both groups, the majority of children (63.6% HIV infected and 71% HIV uninfected) were 
attending a school for children with special educational needs rather than a mainstream 
school (12.1% HIV infected and 3.3% HIV uninfected). Twenty-five percent of HIV 
uninfected participants, compared to nine percent of HIV infected participants had 
repeated a grade.  In a review of literature highlighting the concern of HIV in adolescence, 
it was reported that 51% of children with HIV fail a grade while 27-33% require special 
education (Laughton et al, 2013). Adverse neurocognitive deficits affects both groups of 
children and is widely reported. In children with CP this may be as a result of direct injury 
to the brain which results in white matter tracts being disrupted leading to impaired 
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processing, attention and executive function and can lead to cognitive and intellectual 
impairments (Brossard-Racine et al, 2012; Bottcher, 2010). This can lead to children with 
CP requiring special schooling. Similarly neurocognitive deficits in children with HIV may 
be as high as 90% (Lowick et al, 2012) and delays can be persistent despite children 
initiating early treatment (Potterton et al, 2016). Furthermore, children with HIVE have 
been shown to perform worse in these areas compared to children who do not have the 
diagnosis of HIVE (Walker et al, 2013). This may be due to irreversible CNS damage early 
on by the virus or ongoing viral CNS replication as a result of poor penetration of 
medication into the CNS or neurotoxicity of HAART (Crowell et al, 2014; Smith et al, 
2009). Persistent cognitive impairment in the presence of good systemic viral control may 
indicate that there is inadequate CNS viral suppression due to poor CNS penetration of 
drugs (Vreeman, 2015).  Invasive measures are required to monitor the viral load as well 
as the penetration of medication in the CNS and is not readily done in children therefore it 
is difficult to know the exact cause of ongoing neurocognitive deficits (Crowell et al, 2014). 
Orphanhood and environmental factors such as poverty, illness, malnutrition and negative 
living environment are known to have an effect on learning and behaviour in both groups 
of children however socioeconomic status was not assessed as part of this study 
(Laughton et al, 2013; Jelsma et al, 2011; Shead et al, 2010).  
Six percent of HIV infected participants and 19% of uninfected participants in this study 
were taking Ritalin which is used for attention and hyperactivity. The prevalence of 
hyperactivity in children with CP was found to be 30% in a developed country. This was 
not associated with poor socio-economic, physical and cognitive characteristics (Brossard-
Racine, 2012). Studies conducted in resource-limited countries have reported hyperactivity 
to be between 20% and 28% among HIV infected children (Donald et al, 2014b; Govender 
et al, 2011) which is similar to the findings of this study. 
5.2.2 HIV 
Seventy eight percent of HIV infected children initiated HAART below the age of one year. 
Only 16% initiated treatment below the age of six weeks. The CHER study advocated for 
early initiation of treatment before the age of seven weeks as the morbidity and mortality 
outcomes are more favourable than if it was deferred (Violari et al, 2008). Children in this 
study were born between the years of 1999 and 2010. The HAART regimen was instituted 
in South Africa in 2004 and initially children had to have an incident of an 
immunocompromised illness or CD4 count less than fifteen percent before HAART was 
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administered (Donald et al, 2015). In 2010 all infants below the age of one year received 
treatment irrespective of clinical stage of disease (Potterton et al, 2013). Therefore the 
majority of children in this study were unlikely to have had treatment from birth and the 
older children in this study (born between 1999 and 2004) may have been severely 
immunocompromised before HAART was initiated. This could possibly explain why there 
is a higher percentage of children initiating HAART between six week and one year. 
Despite initiation under the age of one year, the children in this study are experiencing 
both motor and cognitive deficits. This is consistent with participants with diplegia as a 
result of HIVE who all initiated HAART before the age of one year (Langerak et al, 2013). It 
also fits in with the trend that early initiation improves mortality but doesn’t protect against 
neurological damage (Potterton et al, 2016; Donald et al, 2015; Laughton et al, 2012; 
Smith et al, 2009) 
Viral load is the number of viral particles in the blood stream and is used to monitor a 
patient’s response to HAART (Rutherford et al, 2014). Virological treatment failure is 
defined by VL greater than 1000copies/ml based on two consecutive viral load 
measurements (Kukoyi et al, 2016). In this study, only 12.5% of participants had levels 
above 1000copies/ ml indicating poor virological control.  The viral load for the majority of 
children fell within 20-1000copies/ml which is indicative of adequate viral suppression.   
Inadequate viral suppression can lead to drug resistance and this may have negative long 
term consequences since these drugs are needed from birth (Vreeman, 2015). 
5.3 Anthropometric data 
5.3.1 Height and weight compared to normative data 
There were no significant differences between the groups for weight and height as well as 
weight-for-age and height-for-age z scores.  
The weight-for-age z score fell within the median percentile indicating that children were 
neither under nor over weight. The mean height-for-age z score for both groups was 
approaching -2.0 (-1.61 for HIV infected; -1.75 for HIV uninfected) indicating that in both 
groups participants fell within the fifteenth percentile which shows a trend towards being 
shorter. On further examination, the mean height-for-age z score of the HIV infected non-
functional participants was -2.38. Values below -2.0 indicate severe stunting (WHO 
reference 5-19years). The non-functional HIV infected children were significantly shorter 
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than the functional HIV infected counterparts. Growth failure is prevalent in CP and HIV 
(Hutchings et al, 2013; Feinstein et al, 2012; Bell et al, 2010).  
For both groups malnutrition, poor socioeconomic circumstances as well as inactivity could 
contribute toward decreased height. However, neither nutritional nor socioeconomic status 
was assessed as part of this study. The non-functional group were mainly wheelchair 
bound. They may walk for short distances with assistance. Lack of weight bearing through 
the lower limbs means there is decreased mechanical stress on the bones which in turn 
leads to poor bone growth and result in stunting (Bell et al, 2002). Bone mineral density in 
HIV infected children can be reduced due to the virus itself as well as to increased HAART 
exposure and this may also affect growth in this population (Donald et al, 2014b) 
Malnutrition is unlikely to be a significant cause in children in this study as their mean 
weight-for-age z scores fell within normal limits (-0.91). 
5.3.2 Height and weight and viral load 
Growth failure was one of the hallmarks of HIV infection in children in the pre-HAART era 
(Shead et al, 2010). Additionally, Arpadi (2005) noted that there was no association 
between viral load and growth since the initiation of HAART. The HIV infected participants 
in this study did not show significant signs of growth failure and the majority had adequate 
viral control. However, a moderate significant correlation between viral load and weight 
and height was found to be and this should be carefully interpreted. Since majority of the 
participants in this study had good virological control, there isn’t enough variability in the 
viral load levels to deem this correlation to be meaningful. Furthermore, if there was to be 
a meaningful correlation, one would expect a negative correlation between these 
variables.  HAART is known to have a positive effect on growth and that normal growth 
parameters can be attained after two years of treatment (Feinstein et al, 2012; Sutcliffe et 
al, 2011; Weigel et al; 2010) and this is evident in the participants in this study. 
5.4 Function 
5.4.1 GMFM 
There was no statistically significant difference between the two groups for GMFM. 
However, the reported minimum clinically important difference (MCID) for the GMFM-66 of 
a large effect size (0.8) is 1.3 (Oeffinger et al, 2008). The difference in the mean GMFM 
scores between the HIV infected and HIV uninfected groups was 3.87 which is clinically 
important. This is largely attributed to the difference of 2.36 in GMFM scores between the 
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functional HIV infected group and the functional HIV uninfected group which is also 
clinically important. Within this functional group, the greatest difference in scores (6.3%) 
was noted in Dimension E which is that of walking, running and jumping. This difference is 
also clinically important. The difference between the two non-functional groups was 0.65 
and is not clinically important 
 This clinical important difference in the HIV infected functional group could be attributed to 
the difference in age between the two groups. The HIV infected children were younger 
than the HIV uninfected and this was shown to be statistically significant (p=0.01). The 
mean age of the HIV infected group was 7.5years. Children with spastic diplegia at 
GMFCS I and II attain 90% of their maximum GMFM score between the age of five and 
seven and thereafter they begin to plateau (Beckung et al, 2007; Rosenbaum et al, 2002). 
The function of children with GMFCS I and II remains stable from adolescence into 
adulthood (Hanna et al, 2009).  It is possible then, that the HIV uninfected children had 
already reached a plateau and have a stable function according to the GMFM, while the 
HIV infected group were still perhaps reaching their peak. The extensive research that has 
been done on these motor curves and the stability and decline of function, has been done 
on children with diplegia as a result of CP. Therefore, we need to use them with caution 
when applying them to the results of the HIV infected participants. Since there are no 
longitudinal studies to determine the progression of this group of children, we cannot use 
these curves to prognosticate for the HIV infected group.  
Additionally the significance in the difference in age is evident when comparing the 
percentiles of the GMFM score for the functional groups. The mean GMFM score for HIV 
infected functional children was between the 15-20th percentile and 55th percentile for 
GMFCS I and II respectively. This was better than those of the HIV uninfected group 
whose scores fell with the 10-15th  percentile for GMCS I and 40th percentile for GMFCS II. 
These percentiles measure the relative ability of the participants compared to other 
children of the same age and GMFCS level (Hanna et al, 2008). A moderate positive 
correlation was found between age and GMFM scores of the HIV uninfected, functional 
group. This would mean that as age increases, the GMFM score will increase. The 
potential for improvement in function is always present and in this group, we also know 
that they are unlikely to deteriorate as the progress into adulthood (Hanna et al, 2009). 
Again, even though the functional HIV infected participants in this study are younger and 
performing better than the HIV uninfected participants, we are unable to predict how they 
will continue to function over time. In the non-functional group, both the infected and 
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uninfected groups’ scores fell within the same percentile for GMFCS III (60-65th percentile) 
and GMFCS IV (80-85th percentile).  
For the HIV infected participants, no correlation was made between GMFM and viral load 
and GMFM and age. This could be due to the small sample size or the fact that the 
majority of participants had good virological control and so there was not enough variation 
of this variable to make an association. 
Strength and tone can independently as well as in combination have an impact on function 
(Bartlett, 2013; Kim and Park, 2011; Ross and Engsburg, 2007). The effect of strength and 
tone on function for this study will be discussed further on in this chapter. 
5.4.2 Functional Mobility Scale 
The FMS is a measure of the participants’ mobility at home and in the community. There 
were no significant differences between the groups at five, fifty and five hundred meters.   
As expected the HIV infected and uninfected functional group were able to walk 
independently or with an assistive device over a distance of five hundred meters. This 
allows them to have a greater sense of independence when participating in the 
community. The non-functional group were limited to crawling at five and fifty meters and 
wheelchair use over 500 meters. This limits their ability to participate in the community. 
Limitation of independent mobility has been shown to have a negative impact on quality of 
life (Calley et al, 2012). Increased gait pathology in the non-functional groups as well as 
decreased gait speed are also known to negatively impact on social participation (Jaspers 
et al, 2013). A decline in gait function can be caused by an increase in weight as well as a 
decrease in muscle strength (Bell et al, 2002). For both groups the mean weight-for-age z 
scores (-0.67 HIV Infected; -0.66 HIV Uninfected) and BMI-for-age z scores (0.51 HIV 
Infected; 0.03 HIV Uninfected) fell within the median percentile, therefore an increase in 
weight was unlikely be the cause of poor gait function. Poor muscle strength and 
increased spasticity can impact gait and the impact of these will be discussed in the next 
section. These differences also lend support to stratifying the initial sample into functional 
and non-functional groups.  
A range of tools is required to comprehensively assess the function of children with CP 
(Debuse and Bruce, 2011). The GMFM-66 is the most widely used tool but only assesses 
gross motor function in a test environment therefore it may not be a good reflection of how 
a child functions at home (Debuse and Bruce, 2011) while the FMS is the only measure to 
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assess a child’s mobility using various assistive devices as well as in different 
environments (Harvey et al, 2008). These two outcome measures were used together to 
get a more complete assessment of activity (GMFM-66) and participation (FMS). 
In conclusion, there was no statistical difference between the groups in terms of function 
and mobility thereby rejecting the null hypothesis.  However, a clinically important 
difference was observed in favour of the HIV infected functional participants with regard to 
the GMFM especially Dimension E. However, no significant difference was noted between 
the HIV uninfected and infected functional participants in the FMS. As we know this group 
consisted of children with GMFCS level I and II therefore, they are able to walk 
independently. The FMS as a tool serves to report whether a participant can mobilise over 
a specific distance only while Dimension E of the GMFM looks at other components of 
walking like balance, running and stepping over objects. Therefore, this could explain why 
a greater difference was observed in walking with the GMFM as opposed to the FMS as it 
is more detailed and specific. Furthermore, there are no reported MCID values for the 
FMS. 
5.5 Impairments 
5.5.1 Muscle Tone 
Four muscle groups were tested bilaterally using MAS. No significant differences were 
found between the HIV infected and HIV uninfected groups except for the right adductor 
tone in the non-functional group. 
 The HIV infected non-functional participants had mild tone compared to the HIV 
uninfected participants who had a greater frequency of severe tone particularly in the 
proximal adductor muscles. This increase in severe tone proximally could be the cause of 
limited ability to walk in children that were HIV uninfected and non-functional. This 
however, cannot be applied to the HIV infected group as they had a greater frequency of 
moderate tone proximally. Their inability to walk can perhaps be attributed to a decrease in  
their muscle strength which will be discussed further in section 5.5.2. 
In order to comment on the cumulative difference in muscle tone, an average percentage 
of frequency across the two sides for each muscle group tested was calculated. This 
enabled the researcher to identify patterns between the two groups based on the 
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frequency of mild tone (graded 1 and 1+), moderate tone (grade 2) and severe tone 
(graded 3 and 4) in the functional and non-functional groups. 
In the functional group, the frequency of mild spasticity was prevalent from proximal to 
distal in both groups. There were no participants with severe adductor tone (proximal) in 
the HIV infected group while the HIV uninfected group had no participants with severe tone 
in the plantarflexors (distal). The predominance of mild spasticity in the HIV infected group  
is consistent with group one in the study by Langerak et al (2014) who also had mild tone 
as well as a gait pattern that was closer to normal. However, almost a third of the HIV 
uninfected group presented with severe tone in their hamstrings. This could have a 
negative impact on gait in this group which could explain why this group scored 6.3% 
lower in Dimension E of the GMFM. 
The HIV infected non-functional group still showed a predominance of moderate tone 
proximally and mild tone distally. Even though the HIV uninfected participants in this group 
had a predominance of severe tone proximally, there was also a distinct decrease in the 
severity of tone from proximal to distal. The results for both groups are inconsistent with 
two studies which have found tone to increase in severity from proximal to distal (Langerak 
et al, 2014; Ross and Engsburg, 2002). A possible explanation for this could be the fact 
that over 50% of the participants in both groups have had Botox at some point as an 
intervention to reduce spasticity in certain muscle groups. Administration of botox in the 
HIV infected group ranged from six months to a year (37%) prior to testing, to more than 
two years (16%) prior to testing. Similarly in the HIV uninfected group, 44% received Botox 
between six months and a year prior to testing while 28% received it more than two years 
prior to testing.  This is in contrast to the study by Langerak et al (2014), where the 
participants had no Botox into the lower limbs prior to testing. 
The HIV infected participants in this study had a predominance of mild tone from proximal 
to distal. Langerak et al (2014) found spasticity to increase from proximal to distal in the 
participants with a more pathological gait pattern. A decreased lean body mass as well as 
muscle atrophy are known complications of HIV as well as HAART. Furthermore, fat is 
redistributed centrally resulting in additional lipoatrophy peripherally in the limbs. This 
results in muscle weakness and wasting (Arpadi et al, 2014; Schiller, 2004; Grinspoon and 
Mulligan, 2003). This wasting and atrophy could possibly explain why there is mild tone 
however there are no studies that have described the quality and pattern of tone that is 
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prevalent in children with diplegia as a result of HIVE even though studies have reported 
spasticity and hyperreflexia as signs of HIVE (Donald et al, 2015; Govender et al, 2011).   
Bartlett et al (2013) noted that spasticity is a primary impairment in CP and spastic 
muscles are known to be weak (Thompson et al, 2011). Therefore these results cannot be 
considered in isolation. The results of muscle strength testing will be further discussed. 
5.5.2 Muscle strength 
There were no consistent statistical differences between the two groups for all muscle 
groups tested. However the following trends were observed. 
Muscle strength was weaker distally in the ankles compared to the proximal hip muscles 
for both infected and uninfected groups which is consistent with that of several studies that 
found muscle weakness to be more prevalent distally than proximally in children with CP 
when compared to normally developing children (Langerak et al, 2014; Ferland et al, 2012; 
Nyström et al; 2008; Wiley and Damiano, 1998). This could be as result of increased 
tightness in the gastrocnemius muscle when the knee is in extension therefore not 
allowing the muscle to produce an effective force (Wiley and Damiano, 1998). Additionally, 
the gastro-soleus complex is known to have a smaller cross-sectional area and is 
therefore unable to an adequate force that is required for function as there is incomplete 
activation of the muscle (Elder et al, 2003).  
It is of great clinical significance to not that in the functional groups, the HIV infected 
participants were weaker than HIV uninfected participants in all muscle groups tested 
except ankle plantarflexion bilaterally. There is a correlation between plantarflexor strength 
and gait and the plantarflexors are crucial in generating the power that is required for gait 
(Nyström et al, 2011) in children with diplegia and GMFCS level I and II. The stronger 
plantarflexors in HIV infected participants could explain why this group performed 6.3% 
better in Dimension E of the GMFM which is that of walking, running and jumping 
compared to the HIV uninfected group. 
Conversely the HIV infected participants in the non-functional group were stronger than 
HIV uninfected participants in all muscle groups except right knee extension and left hip 
abduction. The HIV infected participants had a predominance of moderate to mild tone as 
compared to the HIV uninfected groups who had more severe tone proximally. This could 
have allowed the HIV infected participants to move more easily through the range of 
movement and therefore produce a greater force.   
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Within the HIV infected group, the non-functional participants were weaker than the 
functional participants in all muscle groups tested except left elbow extension and right 
knee flexion. The difference in strength between the groups was greater in the lower limb 
muscles. The non-functional participants were 11.8% weaker in the left hip adductor and 
27.3% weaker in the left hip flexor compared to the functional group. This was also true for 
the HIV uninfected participants where the muscle strength in all muscle groups was 
stronger in the functional group. The weakness of the non-functional HIV uninfected 
participants ranged from being 17% weaker in the left ankle plantarflexors to 43.9% 
weaker in the right hip flexors. This is consistent with the findings of Langerak et al (2014) 
who found that the muscle strength of diplegics as a result of HIVE with a more 
pathological gait pattern to be weaker and Thompson et al (2011) who found there to be 
progressive weakness in lower limb strength from GMFCS I to III.  
The largest drop in strength was observed in the hip flexors followed by the knee flexors 
and extensors in the HIV uninfected group and hip flexion and abduction in the HIV 
infected group. This is partly consistent with Thompson et al (2011) who found the drop in 
strength to be most in the hip abductors followed by the knee extensors and with Nyström 
et al (2008) who found the biggest drop in strength to be in the hip abductors followed by 
hip extensors. The muscle strength of hip extensors was not measured in this study. The 
progressive weakness in the hip muscles from GMFCS I to III can explain why children at 
level III have difficulty to stand and walk independently. These muscles provide proximal 
stability in the stance phase and during weight bearing therefore weakness here will make 
it difficult to have stability during standing and walking. Furthermore, hip flexor and ankle 
plantarflexor strength have been associated with walking and stair climbing while hip 
abduction has been associated with running in ambulant children with diplegia (Ferland et 
al, 2012) 
5.5.3 Muscle strength compared to normative data 
5.5.3.1 HIV infected group 
The muscle strength values of 14 muscle groups in the HIV infected group can be 
compared to muscle strength values of HIV infected children who had no indication of 
disability (Humphries et al, 2014) as the method of testing as well as the units of measure 
were the same. On average, the muscles strength of eight upper limb and six lower limb 
groups were 42.8% (34.7%-49.3%) and 70.4% (58.6%-75.8%) weaker respectively, 
compared to the non-disabled group of Humphries et al (2014). Overall in the present 
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study, the lower limb muscles were weaker than upper limb muscles while this was 
conversely true in the non-disabled group.  The predominant weakness of lower limb 
muscles is consistent with diplegia where lower limbs are more affected than upper limbs. 
Humphries et al (2014) assessed children between the age of four and eight with a mean 
age of 6.4years as compared to the current study which included children up to the age of 
16 with a mean age of 7.78 years. Both groups were receiving HAART at the time of 
testing. The weakness of the disabled group could be attributed to HIVE which was not 
present in the comparative group as well as the prolonged negative effect of the virus and 
HAART on muscle strength. Muscle strength may be affected by mitochondrial toxicity 
from the medication or wasting. Muscle bulk was not measured in this study but wasting 
can occur as a result of increased protein demand due to inflammation. Furthermore fat 
redistribution is a known side effect of HAART and results in peripheral lipoatrophy. All 
these factors can result in decreased muscle strength (Dudgeon et al, 2006; Grinspoon et 
al, 2003). 
5.5.3.2 HIV Uninfected group 
Lower limb strength profiles for children with CP were determined by Wiley and Damiano 
(1998), Nyström et al (2008) and Thompson et al (2011). It is difficult to compare the 
values obtained in the present study to the above as there are differences in age range, 
testing position, method and unit of measure used and the way in which the data was 
analysed. However, they all concluded that the lower limb strength of children with diplegia 
were significantly weaker than normally developing counterparts. In the most recent study, 
muscle strength ranged from 43%-90% of the control group (Thompson et al, 2011).  On 
this basis we can conclude that the lower limb muscle strength of HIV uninfected children 
with diplegia is weaker than those of normally developing children. 
There is a complex relationship between spasticity, ROM and selective motor control in 
children with CP (Ostenjø et al, 2004). Spasticity can be regarded as a primary impairment 
while decreased muscle strength can occur as a result of spasticity (Bartlett et al, 2013). In 
contradiction to this Ross and Engsburg (2002) determined that spasticity is not related to 
strength since weakness was present in all children with diplegia while spasticity was not. 
Furthermore, strength has been highly correlated to function (r=0.83) compared to 
spasticity (r=0.27) (Ross and Engsburg, 2007) and this is supported by studies that have 
shown that strength training programmes in children with CP improve GMFM scores and 
gait (Nyström et al, 2008).  Additionally other studies have noted that strength programmes 
are effective in improving strength but not activity (Bania et al, 2016; Scholtes et al, 2008) 
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Therefore it can be seen that this complex relationship exists between impairment and 
function in children with diplegia.  
5.5.4 Summary 
In this study the HIV infected functional group performed better functionally than their HIV 
uninfected counterparts particularly in Dimension E of the GMFM. They tended to be 
weaker in all muscle groups except the plantarflexors and had a predominance of mild 
tone. Even though statistically, the tone of these groups was similar, the HIV uninfected  
group had a higher frequency of severe tone in their hamstrings. Therefore it is possible 
that the HIV infected participants performed better as they had stronger plantarflexors and 
milder tone than the HIV uninfected functional participants. It can be assumed that muscle 
tone may play an important role in function for this population of children, however further 
research is required in with larger sample sizes to confirm this.   
To summarise, both groups had similar strength and tone profiles which have had an 
impact on function and gait. Since there were no significant statistical differences between 
the groups, the null hypothesis can be rejected for muscle tone and muscle strength.    
5.7 Limitations of the study 
The limitations of this study are as follows: 
 The original sample size of the 33 participants in the infected groups and 31 
in the uninfected groups was fair but once the group was divided into 
functional and non-functional groups, the sample size was diminished. This 
could have had an impact on statistical significance and generalisability of 
the results.  
 Parents and caregivers of HIV infected participants were only asked the 
number of ARV medications that were being taken i.e. one, two or three so 
as to determine if they were taking triple therapy. The names of ARV’s were 
not recorded. The side effects of certain ARV medications have been 
implicated in increasing neurological complications, therefore this information 
could have been useful to determine if there was a correlation between the 
groups and type of medication. 
 Muscle tone is defined as a velocity-dependent resistance to passive 
movement at a joint. There is a complex relationship between muscle tone, 
range of motion (ROM) and selective motor control. An increase in muscle 
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tone can result in decreased range of motion at a particular joint which in turn 
affects normal movement (Ostenjø et al, 2004). It is therefore important to 
measure ROM and muscle tone and this was not done in this study. 
 HIV negative participants were not confirmed as being negative using 
objective testing. This was assumed after no signs of HIV infection was found 
in the patients’ hospital file and in the medical history taken. 
 The diagnosis of HIVE was not confirmed by a medical doctor. Children that 
presented with spastic diplegia and were HIV infected were assumed to have 
HIVE. 
 Gait analysis was not done as part of this study and would have been useful 
to give insight into the similarities and differences between the gait patterns 
of the two groups.   
 Nutritional and socioeconomic status of the participants was not assessed. 
5.8 Clinical Implications of the study 
It is unclear what the natural progression of HIV infected diplegics will be as there are 
many factors that could impact function. Lifelong impact of the virus and medication may 
have negative effects. Therefore it is difficult to say whether they will follow the progression 
of CP diplegia and if management like orthopaedic surgery which is known to assist with 
maintaining function in CP will have the same effect on children with HIV. 
Functional and non-functional children with HIV present differently with regards to strength 
and tone. Management in terms of therapy and surgery will need to address different 
problems in these groups and the outcome thereof will also vary as the natural progression 
for this population is not yet determined. 
5.9 Research implications of the study 
Further research is required to compare functional and non-functional groups with larger 
sample sizes to determine if the is a significant difference between the groups in terms of 
function, muscle tone and strength. Correlation between viral load and function may prove 
to be more significant if it is assessed using a larger sample size. 
Further research is required in the adolescent HIV group to determine the natural 
progression of HIV infected adolescents with diplegia.  
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Further gait analysis research, with larger sample sizes, is required to determine whether 
there are similarities and differences in this area between HIV infected and uninfected 
participants. 
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CHAPTER 6 - CONCLUSION 
 
There are many studies done, spanning over decades to better understand CP and spastic 
diplegia as a result of CP. In more recent times there has also been a fair amount of 
research to help us understand HIV encephalopathy in children. Diplegia can be a result of 
HIVE and to date only one study, done in Cape Town, has analysed and described this 
condition.  
To our knowledge, this is the first study to be done to compare the demographics, 
anthropometrics, function, tone and muscle strength of 33 HIV infected children with 
diplegia to 31 HIV uninfected children with diplegia across GMFCS I to IV.  
The two groups were well matched for age and anthropometrics. Demographically, there 
was a greater incidence of prematurity in the uninfected group. The majority of children in 
both groups attended a school for children with special educational needs. All except one 
HIV infected participant was on HAART, with the majority having initiated HAART under a 
year of age (78%) and only 16% below the age of six weeks old. Good virological control 
was evident in the majority (87.5%) of participants.  
Due to the large difference in participation between the GMFCS levels, both groups were 
stratified into a functional group (GMFCS I and II) and a non-functional group (GMFCS III 
and IV) based on their ambulatory ability. 
In the functional group, the HIV infected children were significantly younger and this group 
performed clinically better in the GMFM than the HIV uninfected participants. There were 
no consistent statistically significant differences between the groups for muscle strength 
and tone but there was a trend for the HIV infected group to be weaker and have a greater 
frequency of mild tone from proximal to distal compared to the HIV uninfected group. 
In the non-functional group there was no significant difference for function and no 
consistent significant differences for strength and tone between the groups. However, the 
HIV infected groups tended to be stronger and have a greater frequency of mild rather 
than severe tone from proximal to distal. 
For both HIV infected and HIV uninfected groups, the non-functional participants were 
weaker than the functional participants and lower limbs were weaker than upper limbs. 
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Among the HIV infected participants, the non-functional participants were significantly 
shorter than the functional participants. 
This study highlights that HIV infected and uninfected participants with diplegia may 
present similarly in terms of function, strength and tone. However, further research is 
required with larger sample sizes to verify these results for children of different GMFCS 
levels.  
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Appendix 4 
Information Sheet 
A comparison of the clinical presentation of HIV-infected spastic diplegic children to 
HIV-uninfected spastic diplegic children in a South African setting  
Dear Parent/Caregiver/ Guardian 
My Name is Tasvi Naik. I am currently employed as a physiotherapist at West Rand CP School. As 
part of my Masters degree in Physiotherapy, I will be conducting research. In this study, I would 
like to find out if there are any differences in the way that HIV infected diplegic children present 
compared with HIV uninfected diplegic children in terms of physical function. I would like to invite 
your child to participate in this study. 
What is involved? 
Your child will undergo a once-off assessment of various physical functions at the hospital. This 
assessment will take an hour and a half to complete. The following assessments will be done in 
this time: 
 GMFM-66: this is a standardised assessment tool. Here I will look at the way in 
which your child moves. It has 66 different types of tasks from lying through to sitting, 
standing and then walking. It will help me to have a clear understanding of how your child 
moves. As each activity is performed a score will be given. This test will take 45 minutes. 
 Muscle strength: I will do this using a machine which I will hold against your child’s 
arm and leg. Your child will be asked to push on the instrument as hard as they can and a 
reading will be taken. There will be no pain or discomfort during this test. I will be testing 
arm and leg strength and so your child may be tired after this test. This test should take 20 
minutes to complete. 
 Muscle tone using the Modified Ashworth Scale: this is an assessment of the 
amount of how tight your child’s leg muscles are. During this test I will be feeling how your 
child’s leg muscles react when I move it. He/she will not be required to do anything during 
this test. This test causes no pain or discomfort. It should also take 20 minutes to complete. 
 There are no risks involved with these assessments but your child may be tires at 
the end of the session. 
 I would also like you to please complete a questionnaire which will give me 
information about your child’s medical history, including HIV status and background. This 
questionnaire is available in English. Should you require a translator to help you with the 
form, one will be provided. 
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 Participation in this study will not interfere with his/her current therapy program. 
 You will be reimbursed for transport costs to the hospital up to the value of R50 per 
person.  
Confidentiality 
Information about your child will be kept safe and confidential. All information obtained will be used 
for the study purposes only. No names will be put on any of the study sheets or results. 
Withdrawal 
Your child may withdraw from this study at any time. This will not affect the current therapy that 
he/she receives at the hospital. 
If you are willing to allow your child to participate in this study, please sign the consent form 
provided. If your child is over 6 years old, he/she will also be required to sign an assent form.  
Thank you for taking the time to read this.  
If you have any further questions or worries, please feel free to contact me, my supervisors or the 
chairperson of the Human Research Ethics Committee (Medical). The contact details are available 
below. 
Thank you, 
 
Tasvi Naik    Joanne Potterton   Carolyn Humphries 
(Physiotherapist)   (Supervisor)    (Supervisor) 
083 235 3567    011 717 3718    083 660 2725 
Contact Details HREC 
Ms Zanele Ndlovu- Administrative officer 
011 717-1252 
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Appendix 5  
CHILD Information Sheet 
Hello,   
My Name is Tasvi Naik. I am a Physiotherapist working at West Rand CP School and I am also 
studying further. As part of my studies I would like to find out how diplegic children do things. I 
would like to invite you to be part of this study. 
If you say yes, I will do the following tests: 
 GMFM-66: to see how well you can do certain tasks like lying, sitting and standing. 
This will take 45 minutes. 
 Muscle strength: I will do this using a machine that I will hold against your arm and 
leg. This will give me an idea of how strong your muscles are. This will take 20 minutes. 
 Muscle tone using the Modified Ashworth Scale: this test will give me an idea of how 
tight the muscles in your legs are. It will also take 20 minutes. 
 Altogether we will be busy for an hour and a half. 
I will be able to do all of these tests in one day at the hospital where you go for therapy. 
I will also ask your parents/guardian to answer questions about your health and how you have 
been growing. 
Any information that I get from your parents and from the tests will be kept safe and private. Your 
name as well as your parents’ names will be kept a secret. 
You may say ‘No’ if you do not want to take part in the study. You will still be doing your normal 
physio exercises even though you are taking part in the study. If at any time you want to stop the 
study, you may do so. This will not change your therapy at the hospital. 
If you would like to help with this study, please sign the form provided. 
You are welcome to ask me questions at any time. 
Thank you for taking the time to read this. 
Tasvi Naik 
(Physiotherapist)0832353567 
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Appendix 6 
Consent Form: 
Research Tiltle: A comparison of the clinical presentation of HIV-infected spastic 
diplegic children to HIV-uninfected spastic diplegic children in a South African 
special school setting  
 
I ______________________ have read the information sheet and understand the purpose of the 
study. I give/ do not give (please circle your choice) consent for my 
child_______________________ to participate in this study. I am aware that my child may 
withdraw at any time without any consequences. I understand that the procedures in the study will 
not harm my child. 
 
________________________                                _____________________ 
(Parent/ Guardian Signature)    Date 
 
 
________________________                               ______________________ 
Researcher Signature   Date 
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Appendix 7 
Assent Form (To be used for both groups) 
Research Title: A comparison of the various clinical presentations of spastic diplegic 
children in a South African setting  
 
I ______________________ am happy/ not happy (please circle your choice) to take part in this 
study. I have read the information sheet and all my questions have been answered. I understand 
that I can stop at any point without any problems. I understand the tests that will be done and that 
they will not cause me harm in any way. 
 
________________________                                _____________________ 
(Child Signature)    Date 
 
________________________                               ______________________ 
Researcher Signature   Date 
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Appendix 8 
Parent Questionnaire 
 
SUBJECT NO: 
 
DOB 
Telephone No:  
BACKGROUND  
DIAGNOSIS – Please 
be as thorough as you 
can 
 
HIV Status:__________________ 
If Positive, Please state at what age your child was diagnosed:_____________ 
Is your child aware of his/her status? Yes     No 
MEDICATION- Please 
list all the medication 
(acute as well as 
chronic)  that the child 
is on as well as when 
they commenced this 
medication 
 
 
Birth History  
 
full term    prem_______(weeks)    Normal Delivery     Caesar     Birth wt________ 
Complications during 
pregnancy____________________________________________________________ 
_____________________________________________________________________ 
Complications at 
birth__________________________________________________________________ 
______________________________________________________________________ 
Complications after 
Birth__________________________________________________________________ 
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______________________________________________________________________ 
Developmental 
Milestones 
 
Sat___________crawled___________    walked_________      first words_________ 
 
First Sentences__________________ 
Family history- 
Please record if parents 
are deceased/ if there 
are any family illnesses 
 
 
Medical & Surgical 
history- please record 
any hospital 
admissions, surgery 
here 
 
 
 
 
 
 
 
School history- 
 Please record when 
your child started 
school, names of 
schools as well as 
current grade 
 
Age when child started school______________________________________ 
Current Grade___________________________________________________ 
Current School___________________________________________________ 
Grades repeated__________________________________________________ 
_______________________________________________________________ 
Other information_________________________________________________ 
_______________________________________________________________ 
Appendix 9 
Data Collection Sheet 
1. Subject no:________________________ 
2. Subject Age:_______________________ 
3. Group:____________________________ 
4. Weight__________________  Height:__________________ 
5. Medications:_______________________ 
6. GMFCS:___________________________ 
 
7. GMFM-66 Score:____________________ 
Dimension A: Lying and Rolling  
Dimension B: Sitting  
Dimension C: Crawling & kneeling  
Dimension D: Standing  
Dimension E: Walking,running & jumping  
 
8. Modified Ashworth Scores: 
Muscle Score 
 L R 
Hip Adductors   
Hamstrings   
Gastrocnemius   
Soleus   
 
Score Description 
0 No increase in muscle tone 
1 Slight increase in muscle tone, manifested by a catch and release or by minimal 
resistance at the end of range of motion when the affected part is moved in flexion or 
extension 
1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance 
throughout the remainder (less than half) of the ROM 
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2 More marked increase in muscle tone through most of the ROM, but affected parts 
easily moved 
3 Considerable increase in muscle tone, passive movement difficult 
4 Affected parts rigid in flexion or extension 
 
9. Muscle strength results: 
Muscle/movement Score 
Trial 1 Trial 2 Average 
 L R L R L R 
Shoulder Abduction       
Shoulder forward flexion       
Elbow flexion       
Elbow extension        
Hip Abduction       
Ankle Plantar flexors       
Knee flexion       
Knee extension       
Hip flexion       
 
 
 
10. Additional Comments: 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
______________________________________________ 
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Appendix 10 
Methodology for assessing spasticity using the Modified Ashworth Scale 
o The examiner will position the child correctly. The child will be asked to relax during 
this assessment. He/she will not be required to do any of the movements actively. It will 
be done for by the examiner.  
o Hip Adductors- the child will be in a supine position with hips flexed at 45 degrees 
and knees relaxed in extension. Examiner supports proximally at greater trochanter. 
The other hand is placed proximal to the ankle. The knee is now taken from maximum 
hip adduction to maximum hip abduction. 
o Hamstring- the child in supine position with head and neck aligned. The hip is flexed 
to 45 degrees for clearance of the heel during knee flexion. Examiner places one hand 
proximal to the knee and one hand proximal to the ankle. The knee is taken from 
maximal flexion to maximal extension. 
o Gastrocnemius- supine with head and neck aligned. Hips are flexed 45 degrees and 
the knee at maximum extension. The examiner stabilises the leg with one hand 
proximal to the knee and other hand grasps the plantar aspect of the foot with thumb 
on lateral surface of the heel and fingers on medial surface. The ankle is taken from 
maximal plantar flexion to maximal dorsiflexion. 
o Soleus- supine with head and trunk aligned. Hip and knee are both flexed at 45 
degrees. The examiner stabilises the leg with one hand proximal to the ankle and other 
hand grasps the plantar aspect of the foot with thumb on lateral surface of the heel and 
fingers on medial surface. The ankle is taken from maximal plantar flexion to maximal 
dorsiflexion. 
o Results will be recorded on a data collection sheet after measurement has been 
taken (Appendix 9) 
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Appendix 11 
Methodology for assessment of muscle strength using a hand-held dynamometer 
 Muscle strength measurements will include: 
o Shoulder abduction strength 
 Child will be positioned on a firm flat surface in supine, knees flexed and 
arms at sides 
 The assessor will hold the dynamometer against the dorsal surface of the 
forearm 
 The assessor will ask the child to push as hard as he/she can up to the side 
o Shoulder forward flexion strength 
 Child will be positioned on a firm flat surface in supine, knees flexed and 
arms at sides with forearms supine 
 The assessor will hold the dynamometer against the palmer surface of the 
forearm 
 The assessor will ask the child to push up as hard as he/she can keeping 
his/her arm straight 
o Elbow flexion strength 
 Child will be positioned on a firm flat surface in supine, knees flexed and 
arms at sides with forearms supine 
 The assessor will hold the dynamometer against the palmer surface of the 
forearm 
 The assessor will ask the child to bend his/her elbow as hard as he/she can 
o Elbow extension strength 
 Child will be positioned on a firm flat surface in supine, knees flexed, elbows 
flexed to 90 degrees, with forearms supine 
 The assessor will hold the dynamometer against the dorsal surface of the 
forearm 
 The assessor will ask the child to straighten his/her elbow as hard as he/she 
can 
o Hip flexion strength 
 Child will be positioned in sitting with both knees flexed off the table.  
 Assessor will stabilise at the pelvis and place the HHD on the anterior thigh, 
3cm proximal to the patella 
 Assessor will ask the child to push up as hard as he/she can 
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 The alternate leg with be done as above. 
o Hip Abduction strength 
 Child will be positioned in supine with both hips flexed off the surface 
 Assessor will hold the dynamometer on the lateral thigh area, 5cm proximal 
to the knee joint and stabilise at the pelvis 
 Assessor will ask the child to push back as hard as he/she can 
 The alternate leg with be done as above. 
o Knee flexion strength 
 Child will be positioned in sitting with knees flexed to 90 degrees 
 Assessor will place the dynamometer on the posterior calf, 5cm proximal to 
malleoli and stabilise at pelvis and thigh. 
 Assessor will ask the child to bend his/her knee pushing as hard as he/she 
can 
o Knee extension strength 
 Child will be positioned in sitting with knees flexed to 90 degrees 
 Assessor will place the dynamometer on the anterior tibia, 5cm proximal to 
malleoli and stabilise at pelvis and thigh 
 Assessor will ask the child to straighten his/her knee pushing as hard as 
he/she can 
o Ankle Plantar flexors 
 Child will be positioned in supine with hips and knees flexed to 90 degrees 
and ankle in neutral 
 Assessor will place the dynamometer on the plantar surface of the 
metatarsal heads and stabilise the pelvis and lower leg 
 Assessor will ask the child to push his/her foot as hard as he/she can 
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Appendix 12 GMFM Score Sheet
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Appendix 13  The Functional Mobility Scale 
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Appendix 14 The Gross Motor Curves 
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Appendix 15 South African Antiretroviral Treatment Guidelines for Children 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
Appendix 16 Correlation Analyses 
 
1. Correlation Analysis between GMFM and Age 
Group Pearson’s Correlation (r) Probability Value (p) 
HIV infected 0.18 0.12 
HIV uninfected 0.43 0.02** 
Functional HIV infected 0.18 0.5 
Functional HIV uninfected 0.66 0.03** 
Non functional HIV infected 0.2 0.4 
Non functional HIV uninfected -0.2 0.5 
* Correlation was significant at the 0.1 level (2-tailed) 
** Correlation was significant at the 0.05 level (2-tailed) 
 
2. Correlation analysis between Viral Load and Muscle strength 
Muscle Group Pearson’s Correlation (r) Probability Value (p) 
Shoulder Abduction Left 
0.37 0.03** 
Shoulder Abduction Right 
0.22 0.24 
Shoulder Forward Flexion 
Left 
0.22 0.23 
Shoulder Forward Flexion 
Right 
0.36 0.04** 
Elbow Flexion Left 
0.30 0.09 
Elbow Flexion Right 
0.27 0.14 
Elbow Extension Left 
0.23 0.21 
Elbow Extension Right 
0.22 0.23 
Hip Abduction Left 
0.14 0.45 
Hip Abduction Right 
0.06 0.74 
Ankle Plantarflex Left 
-0.03 0.89 
Ankle Plantarflex Right 
0.02 0.92 
Knee Flexion Left 
0.42 0.02** 
Knee Flexion Right 
0.18 0.33 
Knee Extension Left 
0.46 0.01** 
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Knee Extension Right 
0.48 0.01** 
Hip Flexion Left 
0.35 0.05** 
Hip Flexion Right 
0.19 0.31 
* Correlation was significant at the 0.1 level (2-tailed) 
** Correlation was significant at the 0.05 level (2-tailed) 
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